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1. INTRODUCTION 
Adequate reaction of any living organism to environmental changes is essential for 
its survival. To this end, a variety of different control and regulatory systems has been 
developed during the evolution. In the multicellular organisms this task is sophisticated, 
as it is necessary to provide a concerted and coordinated action of the cells within the 
body. It is not surprising that aberrations in intercellular signal transduction pathways 
often lead to the severe disorders. Accordingly, proteins participating in signal 
transduction represent the most common targets for the medications. 
To interpret extracellular signals, cells maintain a diversity of surface receptors that 
respond specifically to individual stimuli. The five major classes of the receptors include 
(1) cytokine receptors responsible for the crosstalk between cells, (2) integrin receptors 
that mediate interaction of the cells with the extracellular matrix, (3) receptor tyrosine 
kinases that serve as receptors for the growth factors and thus controlling cell proliferation 
and maturation, (4) ligand-gated ion channels that transmit various signals via 
modification of the permeability of the plasma membrane for certain ions and (5) G-
protein coupled receptors (GPCR). The later class of receptors mediates a large variety of 
physiological responses via interaction of the receptor with the heterotrimeric G-proteins 
followed by activation of various second messengers.  
 
1.1 G-Protein Coupled Receptors 
The G-protein-coupled receptors (GPCRs) represent the superfamily of proteins that 
are able to recruit and regulate the activity of the intracellular heterotrimeric GTP binding 
proteins (G-proteins). GPCRs govern the reactions to a wide range of signals, including 
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odours (Gaillard et al., 2004), taste (Hoon et al., 1999; Zhang et al., 2003), light (Filipek 
et al., 2003), hormones and neurotransmitters. GPCRs represent one of the largest protein 
families in the human genome (Lander et al., 2001), and the largest family of the 
membrane receptors. These receptors are involved in regulation of various biological 
functions and represent one of the most important targets for therapeutic treatment. 
All GPCRs possess seven transmembrane domains linked by the alternating 
intracellular (ICL1-ICL3) and extracellular (ECL1-ECL3) loops, with the amino terminus 
located on the extracellular side and the carboxyl terminus on the intracellular side (Fig 
1.1). The extracellular N-terminus and loops, together with transmembrane domains, are 
known to be involved in the interaction of the receptor with the ligand (Gether, 2000). 
Intracellular parts of the GPCR, including the C-terminal domain and the intracellular 
loops (in particular the ICL2 and the ICL3), are known to be important for the G-protein 
recognition and activation (Kobilka, 1992; Savarese and Fraser, 1992; Wess, 1997).  
Although the GPCRs do not show the overall sequence homology, a significant 
homology is found within the defined subfamilies (Gether, 2000). The three major 
subfamilies include the receptors related to the rhodopsin and the β2-adrenergic receptor 
(family A), the receptors related to the glucagon receptor (family B) and the receptors 
related to the metabotrophic neurotransmitter receptors (family C). The receptors for yeast 
pheromones form two minor unrelated subfamilies (family D and E), and four cAMP 
receptors from Dictiostellum discoideum constitute another unique GPCR subfamily 
(family F) (Gether, 2000; Kolakowski, 1994). 
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addition, a majority of the receptors from this family has palmitoylated cysteine(s) in the 
carboxyl-terminal tail (Qanbar and Bouvier, 2003) causing formation of a putative fourth 
intracellular loop (Palczewski et al., 2000). The transmembrane domains of the family A 
receptors are critically involved in the ligand binding (Gether, 2000). The binding crevice 
for the small ligands is formed exclusively by the amino acid residues of the 
transmembrane domains and is deeply buried in the receptor molecule (Tota and Strader, 
1990). In contrast, mutational mapping of the ligand-binding sites in many of the peptide 
family A receptors has demonstrated critical involvement of the N-terminus and the 
extracellular loops for binding of the larger peptide ligands along with the crevice formed 
by the transmembrane domains (Gether, 2000). 
The Family B receptors include approximately 20 different receptors for 
neuropeptides, for example the vasoactive intestinal peptide (VIP), the calcitonin, the 
glucagon and others. The common feature of the family B receptors is a large (about 100 
aa) extracellular N-terminus, containing several cysteines, presumably forming a number 
of disulfide bridges (Fig. 1.1). Similar to the peptide receptors belonging to the family A, 
the binding sites for the ligands in the family B involve the extracellular domains. The 
large amino terminus of the family B receptors seems to play a prominent role in the 
ligand binding, although the additional interactions of the ligand with the extracellular 
loops are also sufficient (Buggy et al., 1995; Stroop et al., 1996).  
The Family C receptors include the metabotrophic glutamate and GABAB receptors, 
the calcium receptors, the pheromone and the taste receptors. These receptors possess a 
very long (about 600 aa) amino terminus and a short and highly conserved third 
intracellular loop (Fig. 1.1). The large amino terminus forms a ligand-binding site (Conn 
and Pin, 1997; O'Hara et al., 1993). 
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An increasing number of studies have demonstrated that the GPCRs do not act as 
monomeric proteins, but often form functional homo- and/or heterooligomers (Angers, 
2002; Ayoub et al., 2002; Germain-Desprez et al., 2003; Issafras et al., 2002). The 
existence of such oligomers has been confirmed by different experimental approaches 
including those in the living cells (Angers et al., 2001). The oligomerisation has been 
suggested to play a role in the various aspects of receptor biogenesis and function. Several 
studies demonstrated that the GPCR dimerisation can occur in the endoplasmic reticulum 
and thus can be important for the correct receptor traffic (Karpa et al., 2000; Margeta-
Mitrovic et al., 2000; Zhu and Wess, 1998). For some GPCRs, ligand-modulated 
dimerisation at the plasma membrane has been proposed (Angers et al., 2000; Cvejic and 
Devi, 1997). Interestingly, heterooligomerization between the distinct receptor subtypes 
has been shown to result in pharmacological properties different from those of the 
individual receptors (Gomes et al., 2000; Jordan and Devi, 1999; Maggio et al., 1999; 
Yoshioka et al., 2001). Moreover, heterooligomerization can change a downregulation 
mode of GPCRs (AbdAlla et al., 2000; George et al., 2000; Jordan and Devi, 1999) and 
the G-protein coupling (George et al., 2000). Thus the discovery of the GPCR 
oligomerisation could have a considerable impact for the drug development. 
 
1.2 G-protein Mediated Signaling 
According to the generally accepted model, the G-protein coupled receptors exist in 
the equilibrium between the inactive and the active states (Riitano et al., 1997; Scheer et 
al., 1996; Schwarts, 1995). In the active states, the receptors can activate the 
heterotrimeric G-proteins, while in the inactive states they are silent in terms of signaling. 
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In the absence of the external stimuli, the equilibrium of the receptor states is shifted 
towards the inactive conformations (Leurs et al., 1998), however a certain fraction of the 
receptors spontaneously assumes the active states. Ligand binding to the receptor can shift 
the equilibrium towards the active (agonist) or the inactive (inverse agonist) state.  
The heterotrimeric G-proteins are composed of the α-subunit (Gα) and the dimer of 
the βγ-subunits (Gβγ) (Fig 1.2). Activation of the receptor results in the replacement of 
the GDP bound to the Gα subunit by the GTP molecule. After that, the heterotrimer can 
dissociate into the separate Gα and Gβγ subunits (Hamm, 1998; Hepler and Gilman, 
1992; Lambright et al., 1996; Mixon et al., 1995; Wall et al., 1995), although some recent 
data suggest that the G-protein activation may also involve the subunit rearrangement 
rather then the dissociation (Bunemann et al., 2003).  
The activated Gα and Gβγ subunits can regulate the activity of the downstream 
effectors such as adenylate cyclases, phospholypases, ion channels and etc. The 
termination of the signal is achieved by hydrolysis of the Gα-bound GTP due to the 
intrinsic GTPase activity as well as by interaction with specific regulatory proteins (i.e. 
RGS proteins) (Doupnik et al., 1997; Druey et al., 1996; Watson et al., 1996). This leads 
to the inactivation of the Gα and to the formation of heterotrimer that is readily available 
for another round of the activation (Fig. 1.2).  
To date, all known G-proteins are divided into four main classes according to the 
amino acid sequence similarity of their Gα subunits. 
The Gs protein class includes Gαs and olfactory Gαolf. The common property of 
Gαs is stimulation of the adenylate cyclases (AC) leading to the increase of cAMP 
concentration. In addition, the Gαs proteins can stimulate L-type calcium channels 
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(Mattera et al., 1989) and inhibit cardiac voltage-dependent sodium channels (Schubert et 
al., 1989). The Golf protein is expressed exclusively in the olfactory neuroepithelium and 
serves to link odorant receptors with the olfactory-specific form of the adenylate cyclase. 
 
Figure1.2. The G-protein activation cycle. A. Inactive GDP-bound Gα subunit assembles with the 
Gβγ complex. B. Activation of the GPCR by the external stimulus promotes exchange of the GDP to 
the GTP and thus activation of the G-protein heterotrimer. C. Activated G-protein heterotrimer 
dissociates from the receptor. At the same time, the GTP-bound Gα subunit dissociates from the 
Gβγ complex. D. The Gα subunit and the Gβγ complex activate the respective effectors. E. The Gα 
subunit hydrolyses the GTP to the GDP, becomes inactive and builds the complex with the Gβγ 
subunits.  
  
 
Effector 1 Effector 2 
A B 
C 
D 
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The class of Gq proteins includes the ubiquitously expressed Gαq and Gα11 
proteins, the Gα14 (present in the lung, kidney and liver tissues), and the Gα15 and Gα16 
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subunits expressed in the myeloid cells and the lymphocyte cells (Simon et al., 1991). The 
G-proteins of this class activate the phospholipase C, an enzyme that catalyses hydrolysis 
of the phosphatydinositol 4,5-biphospate on the two second messengers, the 
diacylglycerol (DAG) and the inositol 1,4,5-triphosphate (I1,4,5-P). DAG activates the 
protein kinase C, while I1,4,5,P promotes release of the intracellular calcium and thus 
activation of the phospholipase A2. Also Gαq directly stimulates tyrosine kinase activity 
in the lymphoma cells (Bence et al., 1997). In addition, the Gαq/11 proteins are shown to 
inhibit neuronal inwardly-rectifying potassium channels (Firth and Jones, 2001). 
The class of Gi/0-proteins includes the nearly ubiquitously expressed Gαi1, Gαi2, 
Gαi3 and Gα0 proteins as well as the brain- and the adrenal platelets-specific Gαz,. It also 
includes the Gαt and the Gαg expressed in the retina and the taste buds, respectively. The 
common property of the Gi/0-protein family is the inhibition of the adenylate cyclase 
activity. Moreover, the Gi and the G0 proteins have been shown to activate the G-protein 
coupled inwardly-rectifying potassium channels (GIRK) (Yatani et al., 1988), to 
inactivate the L, N and P/Q types of calcium channels (Dolphin, 2003), to stimulate the 
phospholipase C and the phospholipase A2 and to activate the mitogen-activated protein 
kinase Erk1/2 (Cano and Mahadevan, 1995). The Gαt subunits stimulate the cGMP-
specific phosphodiesterase in the retinal rods and cones (Stryer, 1986).  
The G12 protein class is composed by the G12 and the G13 proteins, that show the 
relatively low sequence homology with the other G-proteins. These proteins are involved 
in the modulation of small GTPases activity and thus in regulation of the cell morphology 
(Buhl et al., 1995; Kozasa et al., 1998; Suzuki et al., 2003). The G12/13 proteins are also 
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shown to activate an extracellular signal regulated activated kinase (Voyno-Yasenetskaya 
et al., 1996) and the Na+/H+ exchange (Voyno-Yasenetskaya et al., 1994). 
The β and γ subunits of the G-proteins can be considered as functional monomers 
due to their continuous tight interaction. At least five isoforms of β subunits (Watson et 
al., 1994) and six of γ subunits (Cali et al., 1992) have been discovered to date. These 
isoforms can form different combinations. The βγ-complex acts not only as an anchor for 
Gα subunits to form the functional heterotrimer, but also directly mediates a number of 
specific responses, such as the regulation of the GIRK channels, the activation of the 
phospholipases C and A2, the activation of the MAPK and the modulation of some 
isoforms of adenylate cyclase. 
 
1.3 Serotonin (5-hydroxytryptamine or 5-HT) Receptors 
The neuromodulator serotonin is involved in regulation of the variety of sensory and 
motor functions within the CNS and in the periphery. The serotonergic innervation 
originates from the caudal raphe nuclei in ventral part of the brainstem. The serotonergic 
neurons send their projections to all regions of the brain and the spinal cord and some 
targets at the periphery. The raphe system is tonically active, while its activity can be 
modulated by different factors leading to the changes in serotonin release.  
Serotonin mediates its responses via the superfamily of the 5-HT receptors, which 
contains 14 structurally and pharmacologically different receptor subtypes. The 
superfamily is now subdivided into 7 families (Fig. 1.3). Except the 5-HT3 receptor, 
which is the transmitter-gated Na+/K+ channel, all other 5-HT receptors belong to the 
class of the G-protein coupled receptors. 
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Figure 1.3. Phylogenetic Tree of the 5-HT Receptor Family. The superfamily is subdivided into 7 
families. Except the 5-HT3 receptor, which is the transmitter-gated Na+/K+ channel, all other 5-HT 
receptors belong to the class of G-protein coupled receptors. AC- adenylate cyclase, PLC-
phospholipase C, IC- ion channel, „+“-activation, „-“ - inhibition. 
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The 5-HT1 receptor family includes 5 subtypes, from 5-HT1 A to F, that are 
encoded by different genes sharing 40 to 60 % sequence homology. All 5-HT1 receptors 
are found to couple with pertussis-toxin sensitive Gi/0 proteins and to inhibit the adenylate 
cyclase activity (Albert et al., 1996; Boess and Martin, 1994; Saudou and Hen, 1994). The 
members of this family are broadly expressed in the limbic areas of the brain, particularly 
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in the hippocampus (5-HT1A, 5-HT1D, 5-HT1E, and 5-HT1F), the raphe nuclei (5-HT1A, 5-
HT1D, and 5-HT1F), the basal ganglia (5-HT1B, 5-HT1D, and 5-HT1E) and the spinal cord (5-
HT1D). The 5-HT1 receptors can be localized both post- and pre-synaptically, thus 
regulating the release of the 5-HT or of the other neurotransmitters. At the physiological 
level, some of the 5-HT1 receptor agonists provoke the hyperphagia, activate the sexual 
behaviour, administrate the anxiolytic and the antidepressant action and increase the 
locomotion.  
The 5-HT2 receptor family is composed of three receptor isoforms, 5-HT2 A, B and 
C, that are structurally distinct from the other 5-HT receptors (Humphrey et al., 1993). All 
these receptors are coupled positively to the phospholipase C and mobilise the 
intracellular calcium (Barnes and Sharp, 1999) via the heterotrimeric Gq/11 proteins. The 
5-HT2A receptors are distributed post-synaptically in the forebrain (neocortex, enthorhinal 
and pyriform cortex), the caudate nuclei, the nucleus accumbens, the olfactory tubercle, 
and the hippocampus (Barnes and Sharp, 1999). Outside of the CNS, expression of the 5-
HT2A receptor was detected in the lung, the heart and the spleen. The 5-HT2B receptor is 
expressed in the stomach fundus where it mediates the contraction (Barnes and Sharp, 
1999). The 5-HT2C receptor is expressed in the choroid plexus, the substantia nigra, the 
globus pallidus, the cerebral cortex and the olfactory tubercle. Administration of the 5-
HT2C receptor agonists influences locomotion, body temperature, feeding behaviour and 
hormone secretion. Also agonists of the 5-HT2C receptor have anxiogenic effects (Boess 
and Martin, 1994). 
The 5-HT3 receptor is the ligand-gated K+/Na+ channel. It is the only monoamine 
receptor to be associated with the fast synaptic transmission in the brain (Barnes and 
Sharp, 1999). Two homologous receptor subunits, 5-HT3A and 5-HT3B, are essential for 
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the formation of the functional channel. In the brain, it is concentrated in the dorsal vagal 
complex of the brainstem. It is also detected in the hippocampus, the amygdala and the 
superficial layers of the cerebellar cortex. It is predominantly expressed in the 
GABAergic interneurons, where it plays an activating role, thus providing an indirect 
inhibition of pyramidal neurones. Report on the 5-HT3 receptor knock-out mice indicates 
that the behavioural response to certain forms of pain was reduced in these animals (Guy 
et al., 1997).  
The 5-HT4 receptor subfamily consists of the seven splice variants of the same 
gene differing in the sequence encoding for the cytoplasmic C-termini (Barnes and Sharp, 
1999). All 5-HT4 receptors mediate stimulation of adenylate cyclase via the stimulatory 
Gs proteins (Bockaert et al., 1990; Dumuis et al., 1988a). The 5-HT4b receptor is also 
shown to couple with the Gi/0 proteins. In addition, the 5-HT4a receptor has been shown to 
interact with the G13 proteins leading to the RhoA-mediated activation of gene 
transcription, neurite retraction and cell rounding (Ponimaskin et al., 2002b). 5-HT4 
receptors are localized in the collicular neurons, the basal ganglia, the hippocampus, the 
olfactory tubercle, the limbic structures and the pre-Bötzinger respiratory complex. 
Outside of the CNS, the 5-HT4 receptors are found in the gastrointestinal tract, in the 
adrenal glands, in the myocardium and in the bladder. Functionally, the 5-HT4 receptors 
contribute to the facilitation of the cognitive performances (Barnes and Sharp, 1999) and 
to the regulation of the respiratory activity (Manzke et al., 2003).  
The 5-HT5 receptor family consists of two members, 5-HT5A and 5-HT5B. The 5-
HT5A receptor has been identified in mouse, rat and human. The 5-HT5B receptor is also 
expressed in the mouse and rat, but not in the human where the coding sequence is 
interrupted by stop codons (Nelson, 2004). The 5-HT5A receptor has been demonstrated to 
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couple to the Gi/o proteins and to inhibit adenylate cyclase activity (Hurley et al., 1998). 
Both receptors are essentially limited in the distribution to the central nervous system, 
except that the 5-HT5A receptor has also been found on neurons and neuron-like cells of 
the carotid body. Nothing is known about the role of the 5-HT5B receptor in vivo. 
Recently, a mouse line has been developed where the 5-HT5A receptor coding gene was 
knocked out and these animals have been shown to have a diminished increase in the 
LSD-induced locomotion (Nelson, 2004).  
The 5-HT6 receptor is coupled positively to adenylate cyclase via the Gs proteins 
(Sebben et al., 1994). This receptor is shown to be expressed mainly in the CNS, although 
low levels of the receptor have been detected in the stomach and the adrenal glands. In the 
brain, the high levels of the 5-HT6 receptor are present in the striatum, the olfactory 
tubercles, the nucleus accumbens and the hippocampus, being predominantly post-
synaptic to the 5-HT neurones (Barnes and Sharp, 1999). The 5-HT6 receptor appears to 
regulate the glutamatergic and the cholinergic neuronal activity. Recent data suggests that 
it may be involved in the regulation of cognition, feeding and, possibly, affective state and 
seizures (Woolley et al., 2004). 
The 5-HT7 receptors are encoded by a single gene and the gene transcript 
undergoes an alternative splicing leading to the generation of at least four different 
isoforms. The 5-HT7 receptors couple to the proteins of the Gs family, which leads to the 
activation of adenylate cyclase and increase in cAMP formation (Barnes and Sharp, 
1999). In addition, the 5-HT7a receptor stimulates the G12 proteins, which leads to the 
activation of small GTPases of the Rho family and to the stimulation of the transcriptional 
factor SRE (E. Kvachnina et. al., unpublished data). The 5-HT7 receptors are expressed in 
the hypothalamus, the thalamus, the hippocampus and the cortex (Heidmann et al., 1998). 
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At the periphery, the 5-HT7 receptors were found in smooth muscle cells of the blood 
vessels and in the gastrointestinal tract, where they mediate muscle relaxation (Thomas 
and Hagan, 2004). The 5-HT(7) receptors play an important role in control of both the 
circadian rhythms and the sleep (Thomas and Hagan, 2004). 
 
1.4 The 5-HT1A Receptor 
The 5-HT1A receptor (Fig.1.4) is most extensively characterized among the other 5-
HT receptors. It was found to be involved in a number of physiological and behavioral 
effects, such as regulation of mood (Overstreet et al., 2003; Sibille and Hen, 2001), 
neuroendocrine responses (Burnet et al., 1996; Fletcher et al., 1996), body temperature 
(Overstreet, 2002), sleep states (Bjorvatn and Ursin, 1998), neurogenesis (Radley and 
Jacobs, 2002), cardiovascular system (Saxena and Villalon, 1990) and respiratory activity 
(Manzke et al., 2003; Richter et al., 2003). The 5-HT1A receptor ligands are widely used 
in the treatment of the anxiety and the depression disorders (Dompert et al., 1985; 
Peroutka, 1985; Tunnicliff, 1991), and the characterization of the 5-HT1A receptor 
knockout mice has supported the hypothesis that the receptor plays a role in those states 
(Parks et al., 1998). It has been suggested that the 5-HT1A receptor ligands may have 
therapeutic utility in drug addiction (Cheeta et al., 2001), Alzheimer’s dementia 
(Schechter et al., 2002) and some negative symptoms of schizophrenia (Meltzer, 1999). 
Indeed, the selective 5-HT1A receptor blockade has been shown to enhance the signaling 
within the neuronal circuits involved in cognitive processes, thereby suggesting a novel 
therapeutic approach for the treatment of the cognitive disorders (Schechter et al., 2002).  
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The 5-HT1A autoreceptors have been suggested to play an important role in the 
downregulation of firing of the serotonergic neurons in the raphe system. The delay in the 
onset of the therapeutic benefit, observed after the antidepressant treatment with 5-HT1A 
agonists (e. g. bispirone) and selective serotonin reuptake inhibitors (SSRI) has been 
attributed to the slowly developing adaptive changes in the 5-HT1A autoreceptors (Briley 
and Moret, 1993; Lanfumey and Hamon, 2004). On the other hand, recent studies using 
the selective regional rescue of the receptor in the 5-HT1A knockout mice led to the 
conclusion that the postsynaptic 5-HT1A receptors also play a role in the anxiety-like 
behavior (Overstreet et al., 2003).  
Fig. 1.4. Schematic Representation of the Murine 5-HT1A Receptor. The model is based on the 
hydropathisity analysis and the structural evidences from the other GPCR. Putative N-linked 
glycosylation sites are indicated by the small arboreous symbols. Putative palmitoylation is shown by 
the zigzag line (Charest et. al. 1993). 
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The 5-HT1A receptor mediates its responses via the coupling to the pertussis-toxin 
sensitive heterotrimeric G-proteins of the Gi/o families (Albert, 1994; Barnes and Sharp, 
1999; Raymond et al., 1999), with the affinity decreasing in the following order: 
Gαi3>Gαi2>Gαi1>Gα0>Gαz (Lanfumey and Hamon, 2004). The coupling efficiency of 
the 5-HT1A receptor to a given G-protein may be influenced by the type of the receptor 
agonist (Raymond et al., 1993). In addition, regional differences in the G-protein coupling 
to the 5-HT1A receptor have been recently demonstrated (Lanfumey and Hamon, 2004). 
Thus, the 5-HT1A receptor is coupled preferentially to the Gα0 in the hippocampus, to the 
Gα0 and the Gαi3 in the frontal cortex, to the Gαi3 in the dorsal raphe nucleus, and to the 
Gαi1, the Gαi3 and the Gαz in the hypothalamus. The receptor-mediated activation of the 
Gαi-subunits results in the inhibition of the adenylate cyclase (AC) and a subsequent 
decrease of the cAMP levels. This effect was monitored in the hippocampal neurons (De 
Vivo and Maayani, 1986; Dumuis et al., 1988b) as well as in the different cell lines 
(Fargin et al., 1989; Liu and Albert, 1991; Nebigil et al., 1995). Analysis of G-protein 
specificity for the 5-HT1A receptor mediated AC inhibition revealed an unexpected 
complexity. Antisense depletion of the different subtypes of the Gαi-subunit revealed that 
the removal of the Gαi1 eliminated the 5-HT1A receptor induced inhibition of a basal 
cAMP level, whereas the depletion of the Gαi2 and the Gαi3 blocked the 5-HT1A receptor 
action on a Gs-activated adenylate cyclase (Liu et al., 1999). In addition, positive coupling 
of the recombinant 5-HT1A receptor to the cAMP production has been shown in the cells 
expressing the AC2 isoform of the adenylate cyclase (Albert et al., 1999). Besides the 
effects mediated by the Gαi/o subunits, activation of the 5-HT1A receptor leads to the Gβγ-
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mediated activation of the inwardly rectifying K+ channels and the inhibition of the L-
type Ca2+ channels in hippocampal neurons (Andrade et al., 1986; Clarke et al., 1996; 
Zgombick et al., 1989), dorsal raphe nucleus neurons (Clarke et al., 1996) and atrial 
myocytes (Karschin et al., 1991). In recombinant cell lines, the 5-HT1A receptor evokes 
the Gβγ-mediated stimulation of the phosphatidilinositol-specific phospholipase C (PI-
PLC) (Raymond et al., 1991). In addition, the 5-HT1A receptor can activate the mitogen–
activated protein kinase Erk 1/2. By the modulation of the Erk 1/2 activity the 5-HT1A 
receptor may be involved in the regulation of cell proliferation (Raymond et al., 2001), 
neurogenesis (Radley and Jacobs, 2002) and neuroprotection (Adayev et al., 2003). 
 
1.5 Hydrophobic Modifications of the Proteins 
Proteins are often subjected to the different co- and post-translational modifications, 
such as the phosphorylation, the glycosylation or the lipidation. These modifications 
produce an additional level of complexity that is often involved in the regulation of the 
protein functions. The covalent attachment of the lipid moieties represents an essential 
modification found in many proteins. Three types of lipid modifications are recognized so 
far: GPI-anchoring, prenylation and acylation (Fig 1.5). The later includes N-
myristoylation and S-palmitoylation (Bhatnagar and Gordon, 1997; Casey and Seabra, 
1996; Resh, 1999).  
The GPI-anchoring means a post-translational attachment of the 
glycophosphatidilinositol moieties to a target protein. The core structure of the GPI-
anchor consists of ethanolamine phosphate, trimannoside, glucosamine and inositol 
phospholipid. The GPI anchor is attached to the carboxyl terminus of proteins by the 
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ethanolamine head. The process of GPI attachment is catalyzed by the GPI-transamidase 
complex (Ikezawa, 2002) . 
Figure 1.5. Major Lipid Modifications of Proteins. Gly-glycine, Cys-cysteine, Eth-ethanolamine, 
P-phosphate, Man-mannose, GlcN-glucosamine, I-inositol. Prenylation is an irreversible post-
translational modification of the protein by unsaturated fatty acids via the stable thioether bond. 
Myristoylation is a stable co-translational modification of the N-terminal glycine by the saturated 
myristic acid. Reversible S-palmitoylation occurs at the cysteine residues via the thioester-type bond. 
The GPI-anchor consists of the phosphatidil-ethanolamine, trimannoside, glucosamine and inositol 
phospholipid and serves for the attachment of proteins to the outer leaflet of the plasma membrane. 
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Prenylation is a lipid modification involving covalent attachment of either farnesyl 
(15-carbon) or geranyl-geranyl (20-carbon) isoprenoids via the thioether linkages to the 
cysteine residues located near to the C terminus of the target proteins. The prenylation is 
catalyzed by the specific enzymes named protein prenyltransferases, that are classified in 
the two functional classes: the CAAX prenyltransferases and the protein 
geranylgeranyltransferase type I. The prenylation is often required for the proper function 
of the modified proteins, either as a mediator of the membrane association, as a transport 
signal, or as a determinant for the specific protein-protein interactions (Casey and Seabra, 
1996).  
N-myristoylation occurs co-translationally by addition of the 14-carbon saturated 
myristic fatty acid to the N-terminal glycine residue localized within the consensus 
sequence. The myristoylation occurs via the amide bound. It is catalyzed by the specific 
enzyme N-myristoyl-transferase (Raju and Sharma, 1999). Functionally, myristoylation is 
involved in the membrane anchoring of the target proteins (Resh, 1999). 
S-palmitoylation is a reversible attachment of palmitate or other saturated long 
chain fatty acids to the target proteins. The attachment of the fatty acids occurs at the 
cysteine residues via the thioester linkage. The palmitoylation is unique among the lipid 
modifications as it can be reversible and adjustable. Among the cellular palmitoylated 
proteins, polypeptides involved in the signal transduction (e.g. GPCRs, α-subunits of G-
proteins, Ras-protein, endothelial nitric oxide synthase, adenylate cyclase, phospholypase 
C and non-receptor tyrosine kinases) are often targets for this dynamic modification 
(Bijlmakers and Marsh, 2003; Bouvier et al., 1995b; Dunphy and Linder, 1998). 
Meanwhile it is widely accepted that the repeated cycles of palmitoylation and 
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depalmitoylation can be critically involved in the regulation of the signaling processes 
(Cramer et al., 2001; Mumby, 1997; Ross, 1995). 
 
1.6.    Mechanisms of the Protein S-Palmitoylation 
Sites of the palmitoylation. Comparison of the amino acid sequences of the 
palmitoylated proteins does not reveal any consensus sequence for this modification. 
Types of the proteins that undergo palmitoylation are rather diverse and include both 
integral and membrane associated proteins (Linder and Deschenes, 2003). Palmitoylation 
often takes place at the domains that are situated close to the membranes. For example. 
integral membrane proteins, such as the GPCRs, the tetraspanins and the viral 
glycoproteins have been shown to be palmitoylated at cysteine residues located in the 
close vicinity of the membrane. Examples of the dependence of palmitoylation on the 
proximity to the membrane are given by dually lipidated proteins, such as the farnezylated 
and palmitoylated Ras-proteins, the myristoylated and palmitoylated Gi proteins, the Fyn 
kinase and the endothelial nitric oxide synthase. It has been suggested that first 
modification (farnesylation or myristoylation) provides transient association of protein 
with the membrane which allows for consequent palmitoylation.  
Another large group of palmitoylated proteins includes the membrane-associated 
proteins that do not reveal any means of the membrane association except the 
palmitoylation itself. This group includes the postsynaptic density protein PSD95, the Gαq 
subunit and some of the mitochondrial enzymes. Palmitoylation of these proteins seems to 
be independent on their position relative to the membrane, and thus might involve 
different mechanisms.  
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Non-enzymatic palmitoylation. It has been proposed by several research groups that 
the palmitoylation might occur non-enzymatically, and the palmitoylated state of proteins 
can be regulated by the enzymatic depalmitoylation step (Bano et al., 1998; Bharadwaj 
and Bizzozero, 1995; Bizzozero et al., 2001; Duncan and Gilman, 1996); (Duncan and 
Gilman, 1996; O'Brien et al., 1987). However, non-enzymatic palmitoylation has been 
shown only in in vitro assays and needs a non-physiologically high concentration of 
palmitoyl-CoA (Linder and Deschenes, 2003). 
Enzymatic palmitoylation. The majority of data on the protein palmitoylation 
suggests that both palmitoylation and depalmitoylation are catalysed by the enzymatic 
reactions. Palmitoyl Acyl Transferase activity (PAT) has been detected in the membrane 
fractions derived from a variety of cell types (Berger and Schmidt, 1984; Mack et al., 
1987). The PAT activity has been also detected in the membrane preparations enriched in 
the ER, the Golgi and the plasma membrane (Berthiaume and Resh, 1995; Das et al., 
1997; Dunphy et al., 1996; Gutierrez and Magee, 1991; Liu et al., 1996; Ueno and Suzuki, 
1997). Given the diverse nature of the palmitoylated proteins, it would not be surprising if 
multiple protein acyltransferases would be found in different cell types or even within one 
cell type. 
Genetic studies performed in the yeast provided a new insight into the nature of the 
PAT enzymes. Two types of the PATs were isolated from the yeast using the genetic 
screen (Roth et al., 2002; Zhao et al., 2002). Both of the enzymes reveal the cysteine rich 
domains (CRD) containing the conserved DHHC (Asp-His-His-Cys) motifs, that are 
shown to be critical for their PAT activity. The isolated Erf2/Erf4 complex has been 
shown to catalyse protein palmitoylation on the cysteine residues adjacent to the sites of 
farnezylation (yeast Ras2 protein) (Dong et al., 2003). Another yeast protein with the PAT 
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activity, the AKR1, catalyses the palmitoylation of the casein kinase Yck2p via an ATP-
dependent mechanism (Roth et al., 2002). Interestingly, the AKR1 protein seems to be 
capable to palmitoylated cysteines in the absence of any adjacent lipid modification. This 
implies that the AKR1 and the Erf2/Erf4 PATs recognise distinct substrates. Such 
different substrate preferences of the two isolated PAT enzymes correlate with the data on 
structure of the palmitoylated proteins described above.  
Genes encoding for the DHHC-CRD containing proteins are found in all eukaryotic 
genomes examined to date (Linder and Deschenes, 2003). Thus mouse and human 
genomes appear to have approximately 23 DHHC-CRD genes, some of which are 
currently under investigation.  
Enzymatic depalmitoylation. The fact that the rate of the palmitate turnover often 
exceeds that of the protein itself, suggests that the depalmitoylation is an enzymatic 
process. Two kinds of the palmitoylthioesterases, the one lysosomal (PPT1 and PPT2) 
and the other cytoplasmic (APT1) enzymes have been identified and characterised so far 
(Linder and Deschenes, 2003). 
The protein palmitoyl thioesterases PPT1 and PPT2 are localized exclusively within 
the lysosomes (Camp et al., 1994; Soyombo et al., 1999). They play an important role in 
the catabolism of palmitoylated proteins. Deficiency in the PPT1 enzyme was shown to 
be associated with the neurodegenerative disorder, infantile neuronal ceroid lipofuscinosis 
(INCL). Several cell types of the INCL patients reveal an abnormal accumulation of the 
lipidated thioesters derived from the acylated proteins (Lu et al., 1996).  
The cytoplasmic acyl protein thioesterase APT1 has been proposed to be involved in 
the regulation of the palmitate turnover on many cytosolic and membrane proteins 
(Duncan and Gilman, 1998). The purified APT enzyme can cleave both thio- and 
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oxyesters. The APT 1 was shown to regulate the palmitate turnover on the Gαs protein, 
the endothelial nitric oxide synthase and some of the viral proteins (Linder and 
Deschenes, 2003; Veit and Schmidt, 2001). It would be interesting to determine whether 
the APT1 can deacylate the integral membrane proteins such as GPCRs. 
 
1.7 Palmitoylation of the G-protein Coupled Receptors 
As was mentioned above, most of the GPCRs contain conservative cystein residues 
at the cytoplasmic C-terminus, which represent putative palmitoylation sites. In many 
cases palmitoylation of the GPCR was confirmed experimentally by point mutagenesis 
and truncation analysis (Qanbar and Bouvier, 2003). 
Palmitoylation of several GPCRs has been shown to be a dynamic and agonist-
dependent modification. For example, treatment with agonists increased incorporation of 
the palmitate in the β2-adrenergic (Mouillac et al., 1992), the 5-HT4 (Ponimaskin et al., 
2001), the muscarinic acetylcholine m2 (Hayashi and Haga, 1997) and the α2a adrenergic 
receptors (Kennedy and Limbird, 1994). The increased palmitate incorporation was 
interpreted as a facilitated turnover rate of the palmitate on the activated receptors. On the 
contrary, incorporation of the palmitate in the vasopressin V2 receptor was decreased 
upon the agonist stimulation (Sadeghi et al., 1997). For some receptors, such as the 
human A1 adenosine receptor, no dependence of the palmitate incorporation on the 
receptor activation has been observed (Gao et al., 1999). 
Variable roles have been assigned to the palmitoylation of GPCRs (Qanbar and 
Bouvier, 2003). The fact that different effects were observed for various GPCRs upon the 
mutation of the palmitoylated cysteines could reflect individual characteristics of the 
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receptor studied. The functional roles played by the palmitoylation in the curriculum of 
the different GPCRs are summarized below. 
Palmitoylation and cell surface expression of the receptor. Some studies revealed 
that the GPCR palmitoylation may be involved in processing and membrane targeting of 
the receptors. Initial palmitoylation of the GPCRs occurs either in the ER-Golgi 
intermediate or in the early Golgi compartments (Bradbury et al., 1997) and appears to be 
important for the expression of the functional receptors on the cell surface. Intracellular 
trapping of the receptors upon the removal of the palmitoylation sites was demonstrated 
for the rhodopsin (Karnik et al., 1993), the lutropin/CG receptor (Zhu et al., 1995), the 
canine H2 histamine receptor (Fukushima et al., 2001) and the CCR5 cytokine receptor 
(Percherancier et al., 2001). Moreover, the lack of the palmitoylated cysteines can be 
accompanied by the enhanced receptor degradation, as was demonstrated for the 
adenosine A1 receptor (Gao et al., 1999). 
Coupling to the G-proteins and the downstream effectors. Replacement of the 
palmitoylation sites in several GPCRs has also been shown to affect the downstream 
signaling. For example, replacement of a palmitoylation site of the acetylcholine m2 
receptor reduced its ability to couple with the Gα0 and the Gαi proteins (Hayashi and 
Haga, 1997). The nonpalmitoylated human somatostatin receptor type 5 displayed the 
reduced coupling to an adenylate cyclase inhibition (Hukovic et al., 1998), whereas 
mutation of a palmitoylation site in the β2-adrenergic receptor impaired its interaction 
with the Gαs protein (Moffett et al., 1993; O'Dowd et al., 1989). 
Sometimes, palmitoylation plays various roles in the different signaling pathways 
activated by the same receptor. For example, the nonpalmitoylated mutant of the human 
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endothelin A receptor was impaired in coupling with Gαi and Gαq proteins, while its 
interaction with the Gα0 protein was not affected (Doi et al., 1999). Different functions in 
the modulation of the downstream effectors were also attributed to the palmitoylated 
cysteines of the endothelin B (ETB) receptor (Okamoto et al., 1998b). While the 
nonpalmitoylated mutant failed to stimulate the phospholipase C via the Gαq and to 
inhibit the adenylate cyclase via the Gαi, the receptor in which only one of three modified 
cysteines was mutated retained the ability to stimulate the phospholipase C, but not to 
inhibit the adenylate cyclase. On the contrary, in case of the 5-HT4 receptor, the mutation 
of one palmitoylation site increased the agonist-independent coupling of the receptor with 
the Gs protein and the adenylate cyclase.  
In contrast to the above data, lack of palmitoylation does not significantly influence 
coupling of the α2a adrenergic receptor with the G-proteins (Kennedy and Limbird, 1993). 
Similar results were obtained for the lutropin/CG receptor (Kawate et al., 1997), the 
dopamine D1 receptor (Jin et al., 1997), the human A1 adenosine receptor (Gao et al., 
1999) and the human thyrotropin receptor (Tanaka et al., 1998). 
Phosphorylation and desensitization. Desensitization of GPCRs is triggered by 
receptor activation and leads to the uncoupling of the receptor from the signaling. The 
cascade of events that leads to the desensitization is initiated by phosphorylation of the 
receptor by the kinases, followed by interaction of the receptor with the β-arrestin and 
internalization. Palmitoylation of the GPCRs was proposed to play an important role in 
the regulation of receptor desensitization. Thus, palmitoylation-deficient mutant of the β2-
adrenergic receptor was shown to be hyperphosphorylated at the basal level, and its 
phosphorylation did not increase upon the agonist stimulation (Moffett et al., 1993). 
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Taken together with the fact that agonist stimulation promoted an increase of a palmitate 
turnover (Mouillac et al., 1992), palmitoylation of the b2-adrenergic receptor could be 
considered as a molecular switch regulating the desensitization of the receptor by 
changing the accessibility of the phosphorylation sites. Similar conclusions appeared from 
structural analysis of the rat bradikynin B2 receptor, which demonstrated the mutual 
exclusion of palmitoylation and phosporylation at sites located close to each other (Soskic 
et al., 1999).  
In contrary, the acylation-deficient V1a vasopressin (Hawtin et al., 2001) and the 
CCR5 chemokine (Kraft et al., 2001) receptors have been shown to possess decreased 
phosphorylation at the basal and the agonist-activated states. The decrease of 
phosphorylation has been accompanied by the reduced internalization, arguing for a 
coordinated regulation of the receptor palmitoylation, the phosphorylation and the 
endocytosis. 
In several cases palmitoylation has been found to be involved in the internalization 
process. For the CCR5 chemokine (Kraft et al., 2001), the thyrotropin releasing hormone 
(Groarke et al., 2001) and the human somatostatin type 5 receptors (Hukovic et al., 1998), 
mutation of the palmitoylation sites was found to decrease the rate of the agonist-
promoted internalization. In case of the thyrotropin releasing hormone receptor, 
palmitoylation has been shown to be critical for its interaction with β-arrestin (Groarke et 
al., 2001). In contrast, mutation of the palmitoylation sites of the lutropin/CG receptor 
lead to the dramatic increase of the internalization rate (Kawate et al., 1997). 
Following the internalization, many of the GPCRs are subjected to downregulation, 
and palmitoylation has been shown to play a role in this process. Replacement of the 
palmitoylation sites of the lutropin/CG receptor (Bradbury et al., 1997) and the H2 
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histamine receptor (Fukushima et al., 2001) facilitated their downregulation. In contrast, 
mutation of the palmitoylation site of the αA2 adrenergic receptor completely abolished 
the receptor downregulation even upon prolonged agonist stimulation (Eason et al., 1994). 
 
1.8 GPCRs in Lipid Rafts and Caveolae 
“Lipid rafts” represent cell membrane domains enriched in specific lipids and 
proteins. They are characterised by a high glycosphingolipid and cholesterol content in 
the outer leaflet of the lipid bilayer that gives them a gel-like liquid-ordered (Lo) structure 
(Brown and London, 1998). The caveolae that are the invaginated microdomains of the 
plasma membrane (Yamada, 1955), enriched in specific caveolae proteins (caveolin 1, 2 
and 3), glycosphingolipids and cholesterol (Chini and Parenti, 2004), are considered to be 
a subfamily of the lipid rafts The lipid rafts and the caveolae are resistant to the low-
temperature solublization by non-ionic detergents (Brown and London, 1998), and 
therefore are often termed “detergent-resistant membrane subdomains” (DRM). This 
property allows for their biochemical separation due to the differential flotation in the 
density gradients.  
The DRM were found to be involved in the regulation of numerous cell functions, 
including the intracellular sorting of proteins and lipids (Sprong et al., 2001), the 
establishment of cell polarity (Manes et al., 2003), the vesicular transport processes 
(Conner and Schmid, 2003; Johannes and Lamaze, 2002; Nabi and Le, 2003) and the 
cholesterol homeostasis (Ikonen and Parton, 2000). Several studies also demonstrated an 
important role of the DRM in the fine tuning of the signaling processes (Simons and 
Ikonen, 1997). A number of the receptor tyrosine kinases, the G-protein coupled 
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receptors, the G-proteins, the kinases and the phosphatases have been found to be located 
in the DRMs (Foster et al., 2003). Therefore it is believed, that the lipid rafts can assist to 
the efficient signal transmission by organising the interacting elements of one signaling 
system in the close proximity to each other. 
Several GPCRs were shown to be enriched or almost exclusively located in the lipid 
rafts or the caveolae. For example, more than 90% of the gonadotropin-releasing hormone 
(GnRH) receptor are localized in lipid rafts (Navratil et al., 2003). Some receptors are 
represented in the DRMs only by a small fraction. For example, the fraction of the 
oxytocin receptor (OTR) in the lipid rafts comprises less than 10% of total amount of the 
receptor on the membrane (Gimpl and Fahrenholz, 2000). Furthermore, some GPCRs has 
been shown to translocate inside or outside of the lipid rafts/caveolae during 
activation/deactivation (Chini and Parenti, 2004). The DRMs may be involved in 
trafficking and stabilisation of some GPCRs on the plasma membrane (Chini and Parenti, 
2004) and in coupling of the receptors to the certain signaling pathways (Yamaguchi et 
al., 2003). In addition, lipid rafts and caveolae were shown to take part in a clathrin-
independent endocytosis of some GPCRs. 
The targeting signal(s) responsible for the localization of GPCRs in the lipid rafts 
and the caveolae are generally unknown. One of the hypotheses proposes that GPCRs are 
transported to DRM due to the interaction of extracellular parts of the receptor with raft 
gangliosides, analogous to such interaction in a case of the EGF receptor. Other 
researchers believe that an interaction of transmembrane domains with the lipid bilayer, 
especially cholesterol, may dictate the microdomain localization of GPCR. In addition, 
interactions with some proteins could also be responsible for the targeting of GPCRs to 
the lipid rafts or caveolae. For example, several caveolae-localized GPCRs, such as the β-
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adrenergic, the endothelin A and the muscarinic m2 receptors, are known to interact with 
caveolin 1 (Chini and Parenti, 2004).  
One of the mechanisms for the protein targeting into the DRMs is their covalent 
modification by fatty acids, since the long-chain saturated fatty acids may pack well in the 
Lo ordered phase and increase the protein avidity for the sphingolipid/cholesterol-enriched 
domains (Melkonian et al., 1999; Moffett et al., 2000). A number of the palmitoylated 
proteins or the proteins modified by other lipids, such as the α-subunits of the 
heterotrimeric G-proteins, the non-receptor tyrosine kinases (NRTKs) and the endothelial 
nitric oxide synthase (eNOS), are localized mainly in the DRM (Okamoto et al., 1998a). It 
has also been demonstrated, that removal of the fatty acid modifications leads to the loss 
of the protein association with the lipid rafts and caveolae (Moffett et al., 2000; Shaul et 
al., 1996; Shenoy-Scaria et al., 1994; Song et al., 1997). For the GPCRs, the role of the 
fatty acylation for the DRM trafficking remains unclear, as many of the palmitoylated 
GPCRs are shown to be excluded from the lipid rafts. 
 
  
Aim of this work 
 
39
2. AIM OF THIS WORK 
The aim of the present work was to investigate the acylation of the 5-HT1A receptor. 
The following aspects were studied: 
1. Detection of possible hydrophobic modifications of the 5-HT1A receptor  
2. Analysis of the chemical nature of the acylation 
3. Investigation of the dynamics of 5-HT1A receptor acylation 
4. Determination of the palmitoylation site(s) 
5. Functional analysis of the 5-HT1A receptor palmitoylation 
During the experimental work we found that the palmitoylation of the 5-HT1A 
receptor is an irreversible modification. This finding is unique among the multiple data 
published for the palmitoylated signaling proteins because usually this modification is 
dynamic. In addition, we found that the 5-HT1A receptor palmitoylation is not modulated 
by the agonist stimulation. Using the acylation-deficient mutants we analysed the role of 
5-HT1A receptor palmitoylation in the receptor-mediated downstream signaling, including 
the coupling with the inhibitory G-proteins, the inhibition of stimulated cAMP formation 
and the stimulation of the mitogen-activated protein kinase. The analysis revealed that the 
palmitoylation of the 5-HT1A receptor is critical for the receptor-mediated signal 
transduction. Finally, we analysed possible role of the palmitoylation in targeting of the 5-
HT1A receptor to the detergent-resistant plasma membrane subdomains. 
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3. MATERIALS AND METHODS 
 
3.1. Materials Used 
3.1.1. Chemicals 
Applied Biosystems : AmpliTaq Gold PCR Kit 
Amersham Biosciences : ECLTM Western Blot Detection Reagents, Nitrocellulose 
membrane, Blocking reagent,  5-hydroxy[3H] tryptamine trifluoroacetate (107 
Ci/mmol). 
Calbiochem : Cycloheximide 
Genomed: Jetsorb Gel Extraktion Kit 
Corning: 20 µm PVDV membranes mounted in 96-well microplates 
Hartmann Analytic GmbH: [9,10-3H] Palmitic acid (30-60 Ci/mmol). 
ICN: Tran [35S]-label methionine (1000Ci/mmol).  
Invitrogen: Oligonucleotide primers, Cellfectin, Lipofectamin 2000, TC-100 medium, 
DMEM-Glutamax II medium, Genetizin, FCS (Fetal Calf Serum), Trypsin, S.O.C. 
Medium, YT medium. 
Kodak: Kodak X-Omat AR film 
New England Biolabs: Enzymes used in the molecular cloning. 
Nunc: Cell culture plasticware  
PerkinElmer Life Sceince: [35S] GTPγS (1300 Ci/mmol.)   
Qiagen: QIAGEN Plasmid DNA purification Maxi Kit 
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Roth: Ammoniumpersulfat, Ampicillin (Potassium salt), TEMED, Acrylamide, Bis-
Acrylamide, 2-Merkapthoethanol, Glycin, X-gal, IPTG. 
Serva:, Bromphenol blue 
Sigma: 5-Hydroxytryptamine, F-12 HAM nutritient mixture, 8-OH-DPAT, Protein A-
Sepharose CL-4B beads, Gentamicin Sulfate, Kanamicine Sulfate, SDS, 
Ethidiumbromide, Penicillin/Streptomycin solution, PMSF, GDP, GTP, Bacto-
Tryptone, Bacto-Yeast extract, Bacto-Agar, Protein Standard Kit for the protein 
concentration measurements. 
 
3.1.2. Antibodies 
Anti-HA - mouse monoclonal and rabbit polyclonal antibodies (Santa Cruz 
Biotechnology) raised against a 9 amino acids hemagglutinine-tag (YPYDVPDYA). 
Anti-GFP (Abcam) - rabbit polyclonal antibodies raised against a purified Green 
Fluorescent Protein (GFP). 
Anti Gαi3 (Santa Cruz Biotechnology) - affinity purified rabbit polyclonal antibodies 
raised against a peptide mapping at the carboxyl terminus of Gαi3 of rat origin. The 
antibodies also recognise Gαi1 and Gαi2 subunits. 
Anti Gαs (Santa Cruz Biotechnology) - affinity purified rabbit polyclonal antibodies 
raised against a peptide mapping within the amino terminal domain of the Gαs of 
human origin. 
Anti-Gα12 - rabbit polyclonal antibodies raised against the Gα12 protein (Ponimaskin 
et al., 1998) 
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Anti-Gα13 (Santa Cruz Biotechnology) - rabbit polyclonal antibodies raised against 
the N-terminus of the murine Gα13 protein. 
Anti-caveolin 1 (Santa Cruz Biotechnology) - rabbit polyclonal antibodies raised 
against the N-terminal peptide of caveolin 1. 
Anti-CD71 (Santa Cruz Biotechnology) rabbit polyclonal antibodies raised against 
the extracellular domain of the human transferrin receptor (CD71). 
p42/44 (New England Biolabs) – rabbit polyclonal antibodies raised against the 
mitogen-activated protein kinase Erk 1/2. 
phospho-p42/44 (New England Biolabs) - mouse monoclonal antibodies, raised 
against the active form of the mitogen-activated protein kinase Erk 1/2 phosphorylated 
at the residues Threonine 202 and Tyrosine 204. 
Peroxidase conjugated goat anti-mouse and anti-rabbit antibodies (Amersham 
Pharmacia Biotech). 
 
3.1.3. Plasmids: 
pcDNA3.1(-), pcDNA 3.1 (+) Myc/His (Invitrogen) 
pFastBac (Invitrogen) 
pEYFP (Clontech) 
 
3.1.4. Oligonucleotides (Invitrogen): 
HA-1A-Sense: 
5´ - GGAGTGGTACCCACCAT GGATTACCCATACGACGTCCCAGACTACGC 
TATGGATATGTTCAGTCTTGGC – 3´ 
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1A-Antisense: 
5´ - CAGGGGGTACCTATTGAGTGAACAGGAAGGGTC – 3´ 
Cys 417 –Ser Forward 
5’ - GAT CAT CAA GTC CAA GTT CTG -3’ 
Cys 417 –Ser Reverse 
5’ - C AGA ACT TGG ACT TGA TGA TC – 3’ 
Cys 420 –Ser Forward 
5’ - GTG CAA GTT CTC CCG CTG ATG – 3’ 
Cys 420 –Ser Reverse 
5’ - CAT CAG CGG GAG AAC TTG CAC – 3’ 
Cys 417, 420- Ser Forward 
5’ CAA GTC CAA GTT CTC CCG CTG - 3’ 
Cys 417, 420- Ser Reverse 
5’ - CAG CGG GAG AAC TTG GAC TTG – 3’ 
Chimera Sense-KpnI: 
5’ – ATTCCGGTACCGCGAGGGAGATCCCCTTG – 3’ 
Chimera Antisense WT KpnI: 
5’ – ATCATGGTACCGGGCGGCAGAACTTGCAC -3’ 
Chimera Antisense DM- KpnI: 
5’ – ATCATGGTACCGGGCGGGAGAACTTGGAC – 3’ 
 
3.1.5. Buffers: 
Blocking solution: 5% (w/v) ECL blocking reagent in PBS-Tween 
  
Materials and Methods 
 
44
GTPγS buffer A: 50 mM Tris/HCl, pH 7.4, 2 mM EDTA, 100 mM NaCl, 3 mM 
MgCl2 and 1 µM GDP 
GTPγS buffer B: 50 mM Tris/HCl, pH 7.5, containing 20 mM MgCl2, 150 mM NaCl, 
0,5% NP-40, 200 µg/ml aprotinin, 100 µM GDP and 100 µM GTP 
Hepes-EDTA: 20 mM Hepes, 1 mM EDTA, pH 8.0 
Ligand binding buffer: 50 mM Tris (pH 7.7), 0.1 % ascorbic acid, 20 µM pargyline 
Ligation buffer: 50 mM Tris-HCl, 10 mM MgCl2, 10 mM DTT, 1 mM ATP 25 
µg/ml BSA, pH 7.5 
NTEP: 0.5% NP-40, 150 mM NaCl, 50 mM Tris/HCl (pH 7.9), 5 mM EDTA, 10 mM 
Jodinacetamide, 1mM PMSF. glycine, 0.1% SDS, pH 8.4 
P1 buffer: 50 mM Tris-HCl, 10 mM EDTA, 100 µg/ml RNAseA, pH 8.0 
P2 buffer: 200 mM NaOH, 1% SDS (w/v) 
P3 buffer: 3 M CH3COONa, pH 5.0 
PBS: 140 mM NaCl, 3mM KCl, 2mM KH2PO4, pH 7.4 
PBS-Tween: PBS, 0.05 % (w/v) Tween 20 
PCR buffer: 20 mM Tris/HCl, 50 mM KCl, pH 8.4 
Protein electrophoresis separation  buffer: 375 mM Tris-HCl, 3.5 mM SDS, pH 8.8  
TE: 0.01 M Tris-HCl, 7.6 or 7.4, 1 mM Na2EDTA, pH 8.0. 
Protein electrophoresis stacking buffer: 125 mM Tris-HCl, 3.5 mM SDS, pH 6.8. 
Protein loading buffer: 31 mM Tris/HCl, 10% Glycerin, 3% SDS, 0,05 % 
bromphenolblue pH 8.8 
QBT buffer: 750 mM NaCl, 50 mM MOPS, 15 % isopropanol, 0.15 % triton X-100, 
pH 7.0 
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QC buffer: 1 M NaCl, 50 mM MOPS, 15 % isopropanol, pH 7.0 
QF buffer: 1.25 M NaCl, 50 mM Tris-HCl, 15 % isopropanol, pH 8.5 
Restriction buffer 1: 20 mM Tris-HCl, 10 mM MgCl2, 1 mM DTT, pH 7.0 
TAE: 40 mM Tris, 1 mM Na2EDTA, 20 mM acetic acid, pH 8.0 
TE: 10 mM Tris-HCl, 1mM EDTA, pH 8.0 
TNE buffer: 25 mM Tris-Hcl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1 mM DTT, 
10% sucrose, 1% Triton X-100, 1 mM PMSF, 10 µM leupeptin, 2 µg/ml aprotinin 
Transfer buffer: 25 mM Tris/HCl, 192 mM glycine, 20% (v/v) methanol, pH 8.3 
 
All chemicals were purchased from Roth, if not marked otherwise. 
 
3.2.    Recombinant DNA Procedures  
The basic DNA procedures were performed as described by Sambrook et al. 
(Sambrook, 1989). The m5-HT1A cDNA was kindly provided by Dr. Paul R. Albert 
(Ottawa, Canada).  
3.2.1. PCR, Site-Directed Mutagenesis and Cloning  
The PCR primers were designed using the Vector NTI software (InforMaxInc, 
1994-2002). The m5-HT1A cDNA was amplified with the specific primers HA-1A-
Sense and 1A-Antisense to create the 9 amino acids hemaglutinine-tag 
(YPYDVPDYA) at the N-terminus of the receptor. The PCR fragment was ligated to 
the KpnI site of the multiple cloning sites of pcDNA 3.1(-) or pFastBac plasmid 
(Invitrogen). 
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The site-directed mutagenesis of the epitope-tagged 5-HT1A receptor with the 
substitution of the serines for the cysteines at the positions 417 and/or 420 was 
performed by the overlap extension PCR technique (Fig. 3.1) using the 
oligonucleotides containing mutation(s) corresponding to the above substitutions 
(Ponimaskin et al., 1998). First, two partial cDNAs were separately amplified from the 
wild type cDNA using the corresponding mutated sense (Cys 417–Ser Forward, Cys 
420–Ser Forward and Cys 417,420–Ser Forward, respectively) or the antisense (Cys 
417–Ser Reverse, Cys 420–Ser Reverse and Cys 417,420–Ser Reverse, respectively) 
primers and the sense (HA-1A-Sense) or the antisense (1A-Antisense) primers 
corresponding to the start and the end of the receptor cDNA. The two PCR products 
were purified from the agarose gel and used as templates for the second PCR. The 
second PCR reaction was performed using the HA-1A-sense and the 1A-antisense 
primers. The PCR products were purified, cut by the KpnI endonuclease and cloned 
into the KpnI sites of the pFastBac or the pcDNA 3.1 vectors. 
For the construction of the 5-HT1A –YFP chimera (Fig. 3.2), the receptor cDNA 
was amplified with the primers Chimera Sense-KpnI and either Chimera Antisense WT 
KpnI for the wild type or Chimera Antisense DM- KpnI for the C417/420-S mutant 
receptors. The antisense oligonucleotides were designed to anneal at the 3’ end of the 
coding sequence to remove the translation termination signal TAA. The amplified 
fragments were purified, digested with the KpnI enzyme and ligated at the respective 
site of the pEYFP vector (Clontech), so that the YFP coding sequence was located in-
frame at the 3’ end of the 5-HT1A receptor. The nucleotide receptor sequences of the 
clones were verified by the Sanger DNA sequencing of the final plasmid. 
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Figure 3.1. Mutagenesis by the Overlap-Extension PCR. At the first PCR round, two partial 
fragments of the 5-HT1A receptor were amplified from the receptor cDNA with the point mutations 
introduced in the primer sequence. The partial cDNA copies produced in the first round were used as 
the template and at the same time as the primers for the synthesis of the full-length cDNA strains at 
the second PCR round. The full-length cDNA strains were then amplified with the side primers s1 and 
as2. S-sense, as-antisense, ORF-open reading frame (coding part of the sequence), *-the introduced 
point mutation, Kpn1-restriction site. 
5-HT1A cDNA
Kpn1 Kpn1 
ORF
as1
s1
s2
as2
HA-tag
2-nd PCR
Kpn1
*ORF
Kpn1
HA-tag
as2
1-st PCR
*
*
ORF
s1
HA-tag
 
 
 
 
  
Materials and Methods 
 
48
The PCR reactions were performed in 50 µl final volume. The standard PCR 
mixture contents were as follows: the PCR buffer (20 mM Tris/HCl, pH 8.4, 50 mM 
KCl), 2.5 mM MgCl2, 10 pmol/µl of the sense and the antisense primers, 200 µM 
dATP, dCTP, dGTP, dTTP, 20 ng of the template DNA, 1 unit of the DNA 
polymerase (AmpliTaqGold from Applied Biosystems). The amplification was started 
with incubation for 5 minutes at 94oC followed by 30 amplification cycles (94oC 30 
sec, 56oC 45 sec, 72oC 120 sec). In the second round of the overlap-extension PCR, 
20-50 ng of the each of two fragments were used. The amplified fragments were 
purified by electrophoresis in the agarose gel. 
 
 
Figure 3.2. Schematic representation of the YFP-tagged 5-HT1A receptor. CMV promoter- 
cytomegalovirus promoter, YFP –yellow fluorescent protein, KpnI- restriction site, ORF- open 
reading frame.  
 
 
5-HT1A CMV promoter YFP 
ORF 
KpnI KpnI 
 
3.2.2. Agarose Gel Electrophoresis  
The DNA fragments were separated by agarose gel electrophoresis. The 1% 
agarose gels were prepared with TAE buffer. The DNA gels were stained with 
ethidium bromide (0.5 µg/ml in TAE) and the DNA bands were visualised under 
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ultraviolet light. The ethidium-bromide stained bands of DNA were excised from the 
gel and purified with the JetSorb DNA purification kit (Genomed). 
3.2.3. Preparation of PCR products for cloning 
The purified PCR product was treated with the restriction endonuclease KpnI to 
prepare the fragments with the “sticky” DNA ends for efficient cloning in the 
expression vector. The total volume of the reaction mixture was 50 µl. This mixture 
contained restriction buffer 1 (20 mM Tris-HCl, 10 mM MgCl2, 1 mM DTT, pH 7.0), 
100 µg/ml BSA, 1 mg of the purified PCR product and 0.5 units KpnI. The reaction 
was performed at 37 oC for 60 min. The DNA fragments were separated by agarose 
gel electrophoresis and purified by the JetSorb kit prior to the ligation. 
3.2.4. Preparation of Expression Vectors for Cloning  
The expression vectors (pFastbac, pcDNA3.1(-), pEYFP) were digested with the 
restriction endonuclease KpnI as described above, except that 5 µg of plasmid DNA 
and 2.5 units of KpnI were used in the reaction which was performed for 2 h. After 
digestion, the KpnI was inactivated by incubation at 65 oC for 20 min. The sticky ends 
of the digested expression vectors were dephosphorylated by incubation for 1 hour 
with 10 units of calf intestinal phosphatase to prevent self-ligation of the vector. The 
digested and dephosphorylated vectors were purified as described above. 
3.2.5. Ligation  
Ligation reactions were performed for 2 h at RT in 30 µl final volume and 
contained the ligation buffer (50 mM Tris-HCl, 10 mM MgCl2, 10 mM DTT, 1 mM 
ATP 25 µg/ml BSA, pH 7.5), 20 ng of the digested vector, 20-100 ng of the digested 
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PCR product and 800 units of T4 DNA ligase. The ligation mixture was used directly 
for transformation of the DH5α or the DH10Bac E.coli competent cells.  
3.2.6. Transformation of E.coli Competent Cells 
The competent cells were defreesed on ice and placed into 12-ml polypropylene 
tubes. 30 µl of the ligation mixture were added to 100 µl of competent cells and mixed 
gently. After incubation for 30 minutes on ice, the cells were heat-shocked for 45 
seconds at 37°C and placed on ice for 2 minutes, mixed with 900 µl of SOC medium 
and shaked in the water bath for 1h at 37 oC. The cells were collected by 
centrifugation and plated on the YT medium agar plates supplemented with 
appropriate selective antibiotics (50 µg/ml ampicillin for pcDNA3.1 and pFastBac 
vector, or 30 mg/ml kanamycin for the pEYFP vector). The plates were incubated 
overnight at 37°C.  
3.2.7. Analysis of the Clones  
The bacterial colonies were collected with the sterile pipette tip and grown in 2 
ml of the YT medium with the respective antibiotics by overnight shaking at 37oC. 
The plasmid DNA was isolated from the overnight culture by the alcaline lysis 
method. The bacterial cells were centrifugated (1000xg for 5 min) and resuspended in 
0.2 ml of the RNAse –containing buffer P1. The cells were lysed by addition of an 
equal volume of the lysis buffer P2 and incubation for 5 min at RT. The genomic 
DNA was then precipitated by addition of 0.2 ml of the buffer P3 (pH 5.5). The 
precipitated genomic DNA was removed by the centrifugation for 10 min at 20000xg 
at 4oC. The plasmid DNA was precipitated from the supernatant by addition of 
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isopropanol to 45% final concentration and centrifugation for 10 min at 20000xg, 
washed by 70 % ethanol, air-dried and dissolved in 50 µl of the TE buffer (pH 8.0). 
Orientation of the inserts was analysed by digestion of the plasmid DNA with 
the restriction endonuclease PstI. The reactions were performed in 50 µl at 37oC for 30 
min. Each reaction mixture contained the restriction buffer 3 (100 mM NaCl, 50 mM 
Tris-HCl, 10 mM MgCl2, 1 mM DTT, pH 7.9), 500 ng of the DNA and 0.5 U of the 
PstI. The digestion products were analysed by agarose gel electrophoresis. The 
correctly oriented clones produced two fragments of 5342 and 847 bp for the clones in 
the pFastbac vector, 4856, 1435 and 625 bp for the colnes in the pcDNA 3.1(-) vector 
and 4484, 802 and 718 bp for the clones in the pEYFP vector. 
3.2.8. Propagation and Purification of the Plasmid DNA  
The clones with the correct insert orientation were selected for the plasmid 
amplification. For that, 100 µl of the overnight culture was inoculated in the 100 ml of 
the YT medium containing the respective antibiotic and incubated under shaking 
overnight at 37oC. The plasmid DNA was isolated by the alkaline lysis method as 
described before, except for increase of the volumes of the P1, P2 and P3 buffers to 10 
ml each. The precipitated genomic DNA was filtered off with a paper filter, and the 
plasmid DNA was purified from the solution using the Quiagen anion-exchange 
columns. The purification included the equilibration of the columns by flow-through 
of 10 ml QBT buffer and binding of the plasmid DNA with the silica matrix under low 
salt conditions. The binding was followed by washing of the impurities with 60 ml of 
the medium-salt buffer QC. The plasmid DNA was eluted with 15 ml of the high-salt 
buffer QF, precipitated by addition of isopropanol to the final concentration 45% and 
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sedimented by the centrifugation at 20000xg. for 30 min at 4oC. The plasmid DNA 
precipitate was washed with 70% ethanol, air-dried and diluted in 1 ml of TE (pH 8.0). 
The procedure yielded about 1 µg of the pure plasmid DNA. The purified plasmid 
DNA was used for the sequence analysis, for the recombinant baculovirus 
construction or for the cell transfection. 
 
3.3. Cell Culture and Transfection 
3.3.1. Culturing of the Sf.9 Insect Cells  
The Sf.9 cells (Smith et. Al. 1985) were grown in 75-mm2 flasks in 10 ml of TC-
100 medium supplemented with 10% of FCS and 1% of penicillin-streptomycin (PS) 
at 28°C. For sub-culturing, the medium was removed, the cells were scraped from the 
flask in 6 ml of the fresh TC-100 medium and resuspended. One sixth of the 
suspension was transferred into the new flask. 
3.3.2. Construction of the Recombinant Baculovirus (Anderson et. al. 1996).  
The baculovirus system allows to establish efficient overexpression of the 
functional mammalian proteins, and has been successfully used in many studies of the 
protein palmitoylation (Mouillac et al., 1992; Ponimaskin et al., 1998; Ponimaskin et 
al., 2002a; Ponimaskin et al., 2001) and some functional studies of the 5-HT1A 
receptor (Mulheron et al., 1994; Nebigil et al., 1995). For the construction of the 
recombinant baculoviruses encoding for the HA-tagged 5-HT1A wild type and the 
mutants, the Escherichia coli DH10Bac competent cells (Invitrogen) were transfected 
with the pFastbac plasmid DNA containing either the wild type or the mutated 
variants of the 5-HT1A receptor (Fig. 3.3). The DH10Bac cells contain bacmid and 
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helper DNA allowing for the site-specific recombination of the 5-HT1A receptor 
cDNAs in the bacmid. The recombinant bacmid DNA was then purified by alkaline 
lysis and checked for the presence of the 5HT1A receptor cDNA by PCR with the 
receptor-specific primers. The positive bacmid DNA preparations were transfected 
into the Sf.9 cells with the Cellfectin transfection reagent. For that, the cells were 
plated on the 35 mm dishes (8*105 cells/dish) one day before the transfection. The 
Cellfectin reagent was diluted 1 to 100 in the serum-free TC-100 medium. The 100 µl 
aliquot of the diluted Cellfectin was mixed with 200 ng of the purified bacmid DNA 
diluted in 100 µl of the serum-free TC-100 and incubated at room temperature for 30 
min. After the incubation, 900 ml of the TC-100/10% FCS was added, and the 
DNA/Cellfectin mixture was transferred on the plate with the cells. After 4 hours the 
transfection mixture was replaced by 2 ml of the TC-100 medium with 10 % FCS and 
1% P/S. One week after the transfection, the baculovirus–containing culture media 
was collected, purified of the cell debris by centrifugation (20 000 g for 10 min) and 
used for amplification of the recombinant baculovirus. The titres of the amplified 
baculoviruses were adjusted to 1x108 pfu/ml.  
3.3.3. Infection of the Sf.9 Cells with Baculovirus  
The Sf.9 cells (106 cells per dish) were plated on the 35 mm dishes one day 
before the infection and incubated in a humid chamber at 29oC. Next day the cells 
were infected with 105 pfu of the purified baculovirus. The cells were incubated with 
the virus for 60 min, being rocked every 15 minutes. After the incubation, the virus-
containing medium was replaced by the TC-100/10% FCS/1% PS. The cells were 
subjected to the analysis 48 hours after the infection. 
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Figure 3.3. Construction of the Recombinant Baculovirus. The recombinant 5-HT1A cDNA 
cloned into the pFastbac vector was transformed into the DH10Bac cells. Specific recombination 
between the vector and the bacmid DNA inside of the DH10Bac cells at the Tn7 sites led to the 
formation of bacmid DNA containing the 5-HT1A receptor coding sequence. The bacmid DNA 
was purified and transfected into the Sf.9 cells, which allowed for the formation of active 
baculoviruses. The baculoviruses were harvested and amplified to the final titre of 1x108 pfu/ml. 
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3.3.4. Culturing of the Mammalian Cells 
The NIH-3T3 cells were cultured in the DMEM medium supplemented with 
glutaMAX II, 10% of FCS and 1% of PS on 10 cm plates. The CHO-K1 cells were 
cultured in the F-12 Ham medium supplemented with 10% of FCS and 1% of PS. For 
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a subculturing, the cells were treated with 3 ml of 0.05% trypsin (w/v)/0.02% EDTA 
(w/v), resuspended in 6 ml of the respective medium and 1/10 of the cell suspension 
was seeded on the new plate. All mammalian cells were grown at 37°C, 5% CO2 and 
95% humidity and passaged weekly (Phelan 1998).
3.3.5. Transient Transfection of the Mammalian Cells  
The cells (5x105 cells per dish) were plated on the 35 mm dishes one day before 
the transfection. 6 µl of Lipofectamine 2000 were diluted in 200 ml of the OPTIMEM 
medium and incubated at RT for 5 minutes. 3 µg of the DNA were diluted in 200 µl of 
the OPTIMEM medium, mixed with the Lipofectamine 2000 solution and the mixture 
was incubated for 20 min at RT to form DNA/Lipofectamine 2000 complexes. After 
the incubation, 400 µl of the DNA/Lipofectamine 2000 mixture was mixed with 1600 
µl of the culture medium containing 10% of FCS and placed on the plates with the 
cells for 4 hours. Then the transfection mixture was replaced by the culture medium 
with 10% of the FCS and 1% of the PS. The procedures were performed according to 
the manufacturers protocol (Pichet and Ciccarone, 1999).  
3.3.6. Stable Transfection of the NIH-3T3 Cells  
The NIH-3T3 cells were transfected using Lipofectamine 2000. One day after 
the transfection, the cells were trypsinised and 1/40 part of the cell suspension was 
plated on 10 cm dishes. 24 hours after the replating, the selective antibiotic Genetizin 
was added to the culturing media (DMEM/10 %FCS/1% PS) at the concentration of 1 
mg/ml. The concentration of Genetizin was adjusted by the dose-response analysis. 
The cells were grown in the selective medium for two weeks. During the incubation, 
the medium was exchanged every 3 days. Single colonies were collected by the sterile 
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pipette tip, treated with 100 µl of the Trypsin-EDTA, resuspended and plated on 
separate 60 mm dishes. The stably transfected cell lines were tested for the expression 
of the recombinant protein by the Western blot. The amount of the receptor surface 
expression was analysed for the selected positive lines by specific radioligandligand 
binding. 
 
3.4. Protein analysis 
3.4.1. Metabolic Labeling and Immunoprecipitation 
The Sf.9 cells (1,5x106 cells per dish) were grown in the 3.5 cm dishes were 
infected with the recombinant baculovirus encoding for the HA-tagged 5-HT1A 
receptor. After 48 h, the Sf.9 cells were labeled with [35S]-methionine (50 µCi/ml, 
>1000) or [3H]-palmitic acid (300 µCi/ml, 30-60 Ci/mmol) for the time periods 
indicated in the figure legends. In some experiments, 5-HT or 8-OH-DPAT were 
added to the final concentrations as indicated in the figure legends. For some 
experiments, cycloheximide (50 µg/ml) was added 10 min prior to the incubation with 
[3H]-palmitate or [35S]-methionine to block protein synthesis. For the pulse-chase 
experiments the cells were incubated after the labeling with complete TC-100 medium 
supplemented with 100 µM unlabeled palmitate and 50 µM sodium pyruvate. After 
the labeling, the cells were washed once with the ice-cold PBS and lysed in 600 µl of 
the NTEP buffer (0.5% NP-40, 150 mM NaCl, 50 mM Tris/HCl (pH 7.9), 5 mM 
EDTA, 10 mM Iodoacetamide, 1 mM PMSF) for 15 min on ice. The insoluble 
material was pelleted (5 min, 20.000 x g) and the anti-HA antibodies (Santa Cruz) 
were added to the resulting supernatant at the dilution 1:60. After overnight agitation 
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at 4° C, 30 µl of Protein A-Sepharose CL-4B was added, and the samples were 
incubated under gentle rocking for 2 h. After brief centrifugation, the pellet was 
washed twice with the ice-cold NTEP-buffer and the immunocomplexes were released 
from the beads by incubation for 30 min at 37°C in the non-reducing electrophoresis 
sample buffer. The radiolabeled polypeptides were analysed by the SDS-PAGE on 
12% acrylamide gels under the non-reducing conditions and visualized by 
fluorography using Kodak X-Omat AR films. Densitometric analyses of the 
fluorograms were performed by Gel-Pro Analyser Version 3.1 Software. The 
protocols are modified from Current Protocols in Cell Biology (Bonifacino, 2000) 
3.4.2. SDS-Polyacrylamide gel electrophoresis (SDS-PAGE)  
10% polyacrilamide gel was used for the separation of proteins with the size 60-
120 kDa, while 12% gel was used for the separation of proteins with the molecular 
mass below 60 kDa. The proteins in the sample buffer (62,5 mM Tris-HCl, pH 6.8, 
containing 20% glycerol, 6% SDS and 0,002% bromphenol blue) were loaded on the 
top of the gel and migrated under the influence of the applied electrical field from the 
cathode to the anode in the running buffer (25 mM Tris/HCl, 192 mM Glycin, 0.1% 
SDS, pH 8.4). To define the protein size, the molecular weight marker was loaded in 
parallel with the probes. The protocol is modified from Laemli (1970) 
3.4.3. Western blot  
After completion of the electrophoresis, the gel was removed, pre-equilibrated in 
the transfer buffer (25 mM Tris/HCl, 192 mM glycine, 20% (v/v) methanol, pH 8.3) 
and placed on top of the nitrocellulose membrane (0.2 µm pore diameter). Three 
sheets of Whatman filter paper pre-soaked in the transfer buffer were placed above 
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and below of the gel and the membrane. Transfer of proteins to the membrane was 
performed by application of the current (3 mA per 1cm2) for 2 h. 
After the transfer, the membranes were incubated in 5% dry milk solution in the 
PBS-Tween buffer for 30 min and incubated with the primary antibodies dissolved in 
the PBS-Tween overnight at 4oC. The membranes were washed 3 times 10 minutes 
with 30 ml of the PBS-Tween, incubated with the secondary horseradish-peroxidase 
conjugated antibodies for 1 h at RT, washed again and subjected to the detection. All 
the incubations were performed in the PBS-Tween. 
For protein detection, the chemiluminescent ECL Western Blotting Detection 
system (Amersham Biosciences) was used. The membranes were placed on a piece of 
SaranWrap film, covered by the detection reagent and incubated for 1 minute at RT. 
The membrane was covered with the second piece of the SaranWrap and an excess of 
the detection reagent was pressed out. The protein bands were visualised by exposure 
to the Kodak-X-OMAT AR films. The protocol is modified from Laemli (1970) 
3.5.   Hydroxylamine Treatment and Fatty Acid Analysis  
The polyacrilamide gels containing the 5-HT1A receptor labeled with [3H]-
palmitic acid were fixed (10% acetic acid, 10% methanol) and treated overnight with 1 
M hydroxylamine (pH 7.5) or 1 M Tris (pH 7.5) under gentle agitation. The gels were 
then washed in water and rocked for 30 min in dimethylsulfoxide (DMSO) to wash 
out the cleaved fatty acids and visualised by the by exposure to the Kodak-X-OMAT 
AR films. 
For the fatty acid analysis, [3H]-palmitate labeled 5-HT1A receptor was isolated 
by immunoprecipitation and SDS-PAGE. The band corresponding to the receptor 
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protein was excised and fatty acids were cleaved by the treatment of the dried gel 
slices with 6 N HCl for 16 h at 110° C. The fatty acids were then extracted with 
hexane and separated into the individual fatty acid species by thin layer 
chromatography using acetonitril/acetic acid (1:1, v/v) as a solvent. The radiolabeled 
fatty acids were visualized by fluorography. The protocols used were optimised 
previously (Ponimasin et. al. 2001) 
3.6.    Indirect Immunofluorescence 
48 h after the infection, the Sf.9 cells grown on coverslips were fixed with 
paraformaldehyde (3% in PBS) for 15 min. The paraformaldehyde was quenched with 
50 mM glycine for 15 min and the cells were washed three times with PBS. The cells 
were then permeabilized with 0.1% saponin for 5 min and incubated for 1 h with the 
anti-HA antibodies diluted 1:200 in PBS containing 2% BSA (PBS/BSA). The second 
antibodies (anti-mouse Alexa546-conjugated, diluted 1:1000 in the PBS/BSA) were 
applied for 1 h and the unbound antibodies were washed off at every step with PBS. 
Finally, the coverslips were mounted in 90% (v/v) glycerol in PBS. The protocol is 
modified from Donaldson (1998). The cells were monitored with the confocal laser-
scan microscope LSM510 (Zeiss) using the Zeiss filter set 15 (BP 546/12, LP 590) 
 3.7.    Assay for the [35S] GTPγS Binding  
The Sf.9 cells were infected with the respective baculovirus stocks as described 
above. Two days after the infection, the cells were scraped from the dishes, washed 
with 0.9% NaCl supplemented with 2 µg/ml aprotinin and 100 µM PMSF and 
resuspended in 2 ml of Hepes-EDTA containing 100 µM PMSF, 2 µg/ml aprotinin 
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and 10 µg/ml leupeptin. The cells were homogenised by 30 strokes of the Teflon 
pestle (1600 rpm) and the cell debris was removed by centrifugation at 100xg for 5 
min. The supernatant was transferred into new tubes and centrifuged at 16000xg for 
30 min at 4°C. The membrane pellet was washed and resuspended in the Hepes-EDTA 
buffer to adjust the protein concentration to 3 mg/ml. The samples were stored at –
80°C. 
The agonist-promoted binding of [35S]guanosine 5´-(3-O-thio)triphosphate to the 
different G-proteins induced by a stimulation of the 5-HT1A receptors was performed 
according to the method described previously (Ponimaskin et al., 1998). Briefly, 2 µl 
of the membranes from the Sf.9 cells expressing the 5-HT1A receptor wild type or the 
acylation-deficient mutants and the G-protein α subunits (Gi1, Gi2, Gi3, Gs, G12, G13) 
together with the Gβ1γ2 subunits were resuspended in 55 µl of the GTPγS buffer A (50 
mM Tris/HCl, 2 mM EDTA, 100 mM NaCl, 3 mM MgCl2 and 1 µM GDP). After 
addition of [35S] GTPγS (1300 Ci/mmol) to a final concentration of 30 nM, the 
samples were incubated for 5 min at 30°C in the presence or the absence of 1 µM 5-
HT. The reaction was terminated by addition of 600 µl of the GTPγS buffer B (50 mM 
Tris/HCl, pH 7.5, containing 20 mM MgCl2, 150 mM NaCl, 0,5% NP-40, 200 µg/ml 
aprotinin, 100 µM GDP and 100 µM GTP). The samples were incubated on ice for 30 
minutes, mixed with 100 µl of 10% suspension of the protein A-sepharose and 10 µl 
of the antibodies directed against the appropriate Gα−subunits and agitated for 1 h at 
4°C. The immunoprecipitates were washed three times with the GTPγS buffer B, 
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boiled in 0.5 ml of 0.5 % SDS and the radioactivity was measured by the scintillation 
counter. 
3.8.   Assay for the Receptor-Ligand Binding 
3.8.1. Saturation Binding Experiments 
The membranes from the Sf.9 cells expressing the wild type (WT) or the 
mutated 5-HT1A receptors were dissolved in the buffer containing 20 mM Hepes (pH 
8.0), 2 mM MgCl2, 1 mM EDTA, 0.1 mM PMSF, 10 µg/ml leupeptin, and 2 µg/ml 
aprotinin. The binding assay with [3H]5-HT was performed as described previously 
(Butkerait et al., 1995; Hall et al., 1985). Briefly, 100 µl of the ligand binding buffer 
containing 50 mM Tris (pH 7.7), 0.1 % ascorbic acid, 20 µM pargyline and 1 to 250 
nm of [3H]5-HT was added to the aliquot of the membrane fraction containing 20 µg 
of protein. The non-specific binding was determined by the addition of 100 µM of the 
unlabeled 5-HT. After 30 min incubation at 20o C, the reaction mixture was loaded on 
20 µm PVDV membranes (Corning, Germany) pre-soaked in 0.5 % polyetilenimine. 
The membranes were washed with the ice-cold binding buffer and the radioactivity 
was measured by the scintillation counter. The data were fitted with the one-site 
saturation binding model by the Pharmacology module of the Sigma Plot 8.02 
software (SPSSInc., 2002). 
3.8.2. Analysis of the Receptor Surface Expression 
The NIH 3T3 or CHO cells transfected with the receptor cDNA were grown on 
24-well plates, starved in the respective medium without FCS for 16 hours prior the 
assay and washed 2 times with ice-cold PBS. For the ligand binding, the cells were 
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incubated with 50 nM [3H]5-HT or 30 nM [3H] 8-OH DPAT diluted in the culture 
medium with 0.2 % BSA for 60 min on ice. The cells were washed 5 times with ice-
cold PBS and lysed in 0.2 M NaOH. The bound radioactivity was measured by the 
scintillation counter. Non-specific binding was determined by the addition of 100 µM 
unlabeled 5-HT. The protocol is modified from Varrault et. al. (1992) 
3.9.    The cAMP Accumulation Assay  
These experiments were done in collaboration with M. Sebben and A. 
Dumuis, UPR CRNS, Montpelier, France.  
The NIH-3T3 cells were selected for the assay, as these cells do not contain 
specific binding sites for the 5-HT1A agonist 8-OH-DPAT (Varrault et.al, 1992). The 
5-HT1A receptor wild type and the acylation-deficient mutant cDNAs were cloned in 
the pcDNA3(-) vector and transfected in the NIH-3T3 cells by electroporation. Cells 
were diluted in DMEM (106 cells/ml) containing 10% dialysed fetal bovine serum 
(dFBS) and plated into 12-well clusters. Six hours after the transfection, the cells were 
incubated overnight in DMEM without dFBS containing 2 µCi [3H] adenine/ml to 
label the ATP pool. The cells were washed and then incubated in 1 ml of culture 
medium containing 0.75 mM IBMX, 50 µM forskolin plus the drugs indicated in the 
figure legends for 15 min at 37°C. The reaction was stopped by replacing of the 
medium with 1 ml of ice-cold 5% trichloracetic acid. The cAMP accumulation was 
measured as described previously (Dumuis et al., 1988b). The amount of the 
expressed 5-HT1A receptor was measured as described in section 3.8.2. 
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3.10.    Erk 1/2 Phosphorylation Assay 
The Erk phosporylation assay was performed in the CHO cells, as this response 
mediated by the 5-HT1A receptor was first described in the mesenchymal cell line 
(Della Rocca et al., 1999). The CHO cells were grown in the F-12 Ham medium 
supplemented with 10% FCS and 1% PS. For the experiments, the cells (0.5x106) 
grown in the 3.5 mm dishes were transfected with the recombinant 5-HT1A receptor 
using the Lipofectamine 2000 transfection agent. Twenty hours after transfection, cells 
were starved in the F-12 Ham medium with 2% BSA and 1% PS for 16 h. Cells were 
then stimulated for 5 minutes with 10 µM 8-OH-DPAT at 37oC under 5% CO2, 
washed with PBS and lysed in the SDS-PAGE loading buffer. The lysates were 
separated by SDS/PAGE and subjected to Western blot analysis. The membranes were 
probed either with the antibodies raised against the phosphorylated Erk 1/2 (phospho-
p42/44; dilution 1:2000) or against the total Erk (p42/44; dilution 1:1000). To analyse 
the receptor expression, the membranes were probed with the antibodies raised against 
the HA-epitope (dilution 1:1000). The relative amount of the phosphorylated and the 
total Erk 1/2 was quantified by densitometric measurements using the GelPro 
Analyser version 3.1 software. The surface expression of the wild type and the mutant 
receptors was adjusted to 450-500 fmol/mg protein, as assessed by the [3H] 5-HT 
binding. The unspecific binding was determined in the presence of 100-fold excess of 
the specific 5-HT1A agonist 8-OH DPAT.  
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3.11    Separation of the Detergent-Resistant Membranes 
(DRM) by Gradient Centrifugation 
The DRM separation was performed as described before (Harder et al., 1998). 
The stably transfected NIH-3T3 cells were plated on the 35 mm dishes 2 days prior to 
the assay. The cells were washed twice with ice-cold PBS, scraped and centrifugated 
at 1000xg, 4oC. For a cholesterol depletion, the cells were washed 2 times with the 
culture medium without FCS and antibiotics and treated for 45 minutes with 15 mM 
methyl-β-cyclodextrin (MβCD) diluted in the medium without FCS and antibiotics. 
The cells were subsequently lysed on ice for 30 min in the TNE buffer (25 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1 mM DTT, 10% sucrose, 1% Triton X-
100, 1 mM PMSF, 10 µM leupeptin, 2 µg/ml aprotinin) at the protein concentration 
1.2 mg/ml TNE. The lysates were mixed with the double volume of 60% OptiprepTM 
gradient medium (60% iodoxianol suspension in H2O, Nycomed Pharma) to give a 
final concentration of 40 % Optiprep. The lysate/OptiprepTM mixtures (600 µl) were 
placed on the bottom of a 2.5 ml ultracentrifuge tube (Beckman) and overlayed with 
350 µl steps of each 35%, 30%, 25%, 20% and 0% OptiprepTM in TNE (Table 3.1). 
The gradients were centrifugated for 5 h at 50 000 rpm in the TLS-55 rotor of the 
Beckman ultracentrifuge TL-100.  
Six fractions corresponding to the initial gradient steps were collected from the 
top of the gradient (Table 3.1). The proteins from the each fraction were precipitated 
by 10 % TCA. The sediments were washed 2 times with acetone, air-dried, 
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resuspended in the SDS-PAGE sample buffer and analysed by SDS-PAGE followed 
by Western blot. 
 
 
Table 3.1. Characterisation of the OptiprepTM Gradient Fractions 
Concentration 
of OptiprepTM, 
(%) 
40 35 30 25 20 0 
No of fraction 
(bottom-top) 1 2 3 4 5 6 
Density, 
(g/ml) 1,256 1,230 1,204 1,178 1,151 0,041 
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4. RESULTS 
4.1 Expression and Palmitoylation of the 5-HT1A 
Receptor 
A high titre baculovirus stock containing the cDNA of the murine 5-HT1A receptor 
tagged with a HA-epitope at the N-terminus (Fig. 4.1 A) was used for infection of Sf.9 
insect cells. In order to monitor the expression and subcellular distribution of the 
receptor, infected Sf.9 cells were subjected for the immunofluorescence analysis (Fig. 4.1 
B). The HA-tagged 5-HT1A receptors were specifically detected by the anti-HA 
antibodies and localized mainly at the cell surface. The labeling with [35S]-methionine 
followed by immunoprecipitation and SDS/PAGE revealed the single protein band with 
the molecular mass of approximately 46 kDa (Fig. 4.1 B, left panel). This corresponds to 
the predicted molecular mass of the 5-HT1A receptor. The absence of specific bands in 
the immunoprecipitates from the non-infected or the baculovirus wild type infected Sf.9 
cells confirmed that the 46 kDa band indeed represents the 5-HT1A receptor.  
To examine whether the 5-HT1A receptor is acylated, the Sf.9 cells infected with 
recombinant baculovirus were metabolically labeled with [3H]-palmitic acid. Such 
labeling, followed by immunoprecipitation and SDS-PAGE, revealed the single protein 
band of 46 kDa (Fig. 4.1 B, right panel) detectable only in the cells infected with the 
recombinant virus. This result demonstrates that the 5-HT1A receptor efficiently 
incorporates [3H]-palmitate.  
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Figure 4.1. Expression and Palmitoylation of the 5-HT1A Receptor in the Sf.9 Insect Cells. (A) 
Schematic representation of the cDNA encoding for the HA-tagged 5-HT1A receptor. (B) Sf.9 cells 
infected with a baculovirus encoding for the recombinant HA-tagged 5-HT1A receptor or with a 
baculovirus alone (Bac) were subjected to immunofluorescence staining with anti-HA antibodies. 
(C) Sf.9 cells expressing the 5-HT1A receptor were labeled for 2 h either with [35S]-methionine (left 
panel) or with [3H]-palmitate (right panel). Cell lysates were subjected to immunoprecipitation with 
the anti-HA antibodies followed by SDS/PAGE and fluorography. The exposure time was 1 day for 
[35S]-methionine and 7 days for [3H]-palmitate labeling. The molecular weight marker is indicated 
between the panels. Promoter- polyhedrin promoter. 
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Having shown that the 5-HT1A receptor is acylated, we analysed the chemical 
nature of the fatty-acid bond in order to distinguish between the amide-type and the ester-
type fatty acid linkages. In contrast to the amide bond linkage, the S-ester and the 
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hydroxyester linkages are sensitive to the treatment with β-mercaptoethanol (McGlade et 
al., 1987). Moreover, the S-ester bond can be distinguished from the hydroxyester bond 
by its sensitivity to the treatment with neutral hydroxylamine (Kaufman et al., 1984). As 
shown in Fig. 4.2 A, the [3H]-palmitate-derived radioactivity was sensitive to the 
treatment with increasing concentrations of the β-mercaptoethanol. Moreover, treatment 
of the [3H]-palmitate-labeled 5-HT1A receptors with neutral hydroxylamine resulted in the 
cleavage of the label from the receptor (Fig. 4.2 B). These results demonstrate that the 5-
HT1A receptor contains the thioester-linked acyl groups and no fatty acids linked through 
the amide- or the hydroxyester-bonds. To determine the identity of the receptor-bound 
lipids, the fatty acids were hydrolyzed from the gel-purified 5-HT1A receptor and 
separated by thin layer chromatography (TLC). Analysis of the TLC data revealed that 
the 5-HT1A receptor contains only the palmitic acid with no traces of the myristic or the 
stearic acids (Fig. 4.2 C). 
 
4.2   The Palmitoylation of the 5-HT1A Receptor is a Stable 
Modification 
To evaluate the role of the de novo protein synthesis in the receptor palmitoylation, 
the Sf.9 cells expressing the 5-HT1A receptor were incubated with [35S]-methionine or 
[3H]-palmitate in the absence or in the presence of the protein synthesis blocker 
cycloheximid. Surprisingly, this experiment revealed that the blockade of the protein 
synthesis results in the nearly complete inhibition of [3H]-palmitate incorporation into the 
receptor (Fig. 4.3 A). Moreover, the inhibitory effect of the cycloheximid was not 
changed in the presence of the agonist. 
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Figure 4.2. The 5-HT1A Receptor is Modified with Palmitic Acid Attached via the Thioester-
Type Bond. (A) The 5-HT1A receptor was labeled for 2 h with [3H]-palmitate, immunoprecipitated 
and treated with increasing concentrations (5%, 10% or 15%) of β-mercaptoethanol for 30 min at 37 
°C prior to SDS-PAGE and fluorography. (B) The Sf.9 insect cells expressing the 5-HT1A receptor 
were labeled with [3H]-palmitate and subjected to immunoprecipitation and SDS-PAGE. The gel 
was treated with 1 M hydroxylamine (right panel) or 1 M Tris-HCl (left panel) prior to fluorography. 
The fluorogram shown is a representative of two independent experiments. (C) The 5-HT1A receptor 
labeled with [3H] palmitate was immunoprecipitated and then subjected to the fatty acid analysis by 
thin layer chromatography (TLC). The fluorogram of the TLC plate was analysed with Gel-Pro 
Analyser software. The mobility of authentic [3H]-palmitate, [3H]-stearate and [3H]-myristate 
standards are indicated by arrows. 
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Figure 4.3. Palmitoylation of the 5-HT1A Receptor is a Stable Modification. (A) The Sf.9 cells 
expressing the 5-HT1A receptor were incubated for 60 min in the absence or the presence of the 
protein synthesis blocker cycloheximide (50 µg/ml) and either 1 µM 5-HT or vehicle (H2O). In 
parallel with the cycloheximide treatment, the cells were labeled with [3H]-palmitate or [35S]-
methionine. The cell lysates were then subjected either to immunoprecipitation, SDS/PAGE and 
fluorography or to Western blot to control the total amount of the 5-HT1A receptor. The fluorogram 
is representative of three independent experiments. (B) The Sf.9 cells were labeled with [3H]-
palmitate or [35S]-methionine for 1 h and then chased with the medium containing the unlabeled 
palmitate or methionine for the periods indicated. During the chase time, the cycloheximide (50 
µg/ml) was applied. The data demonstrate that palmitoylation of the 5-HT1A receptor is irreversible 
and occurs shortly after its synthesis.  
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To further analyse the turnover rate of the 5-HT1A receptor bound palmitate, we 
performed long-time pulse-chase experiments (Fig. 4.3 B). For that, purpose, the Sf.9 
cells expressing the receptor were labeled with [3H]-palmitate or [35S]-methionine for 1 h 
(pulse), and the labeled cells were incubated in the medium without the labels, containing 
cycloheximide, for 3, 9 or 24 h (chase). As shown in the figure 4.3 B, the life-time of the 
[3H]-palmitate labeling corresponds to the life-time of the receptor itself, demonstrating 
that no cleavage of the fatty acids from the receptor occurs during the chase period. 
Taken together, these data suggest that the palmitoylation of the 5-HT1A receptor is a 
stable modification rather being limited to the pool of the newly synthesized receptor.  
 
4.3.  Activation of the 5-HT1A Receptor Does Not Affect 
Receptor Palmitoylation 
It has been previously demonstrated that the palmitoylation of the other member of 
the serotonin receptor family, the 5-HT4(a) receptor, is a dynamic process and that 
stimulation of the receptor by agonist increases the rate of the palmitate turnover 
(Ponimaskin et al., 2001). To test whether palmitoylation of the 5-HT1A receptor may 
also be regulated by agonist, Sf.9 cells expressing the recombinant receptor were treated 
with increasing concentrations of 5-HT during the labeling of the cells with [3H]-
palmitate. The results shown in Fig. 4.4 A demonstrate that the stimulation of the 5-HT1A 
receptor with the agonist does not result in any dose-dependent changes of the receptor 
palmitoylation. Labeling with [35S]-methionine done in parallel demonstrated that the 
expression level of receptor was not affected upon the exposure to agonist (Fig. 4.4 A).  
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Figure 4.4. The Agonist Stimulation Does Not Affect the Palmitate Incorporation in the 5-HT1A 
Receptor.  (A) The Sf.9 insect cells expressing the 5-HT1A receptor were incubated with [3H]-
palmitate or [35S]-methionine for 60 min in the presence of the indicated concentrations of 5-HT. The 
receptor was immunoprecipitated, separated by SDS/PAGE and subjected to fluorography. (B). The 
Sf.9 cells expressing the 5-HT1A receptor alone or co-expressed with the Gi protein (Gαi3β1γ2 
subunits) were incubated with [3H]-palmitate in the presence or the absence of 1 µM 5-HT for the 
indicated time periods. The incorporation of the radiolabel was detected by the immunoprecipitation 
followed by SDS/PAGE and fluorography. The fluorograms are representative of three independent 
experiments. Palmitate incorporation in the 5-HT1A receptor after 5-HT stimulation versus vehicle 
treatment (H2O) during the time-course experiments is shown in (C) as the average (n=3). The range 
of values is shown by bars. The value obtained for the 100 min 5-HT stimulation was set to 1.  
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In order to obtain more detailed information on the dynamics of 5-HT1A receptor 
palmitoylation, we studied the time-course of the agonist-induced incorporation of [3H]-
palmitic acid into the 5-HT1A receptors. As shown in Fig. 4.4 B (control), the intensity of 
the radiolabel incorporation into the receptor increased steadily during the labeling 
period, reflecting the basal level of the palmitoylation. The kinetics of [3H]-palmitate 
incorporation was then studied in the presence of the 5-HT. The results shown in the Fig. 
4.4 B reveal that exposure to the agonist does not influence the efficiency of the 
radiolabel incorporation over the whole labeling period. The effect of agonist stimulation 
on the receptor palmitoylation was further analysed after the co-expression of the 5-HT1A 
receptor with the heterotrimeric Gi-protein (Gαi3-, Gβ1- and Gγ2-subunits). Importantly, 
even in the coupled system, agonist stimulation has no effect on the efficiency of the 
receptor palmitoylation (Fig. 4.4 B). 
 
4.4.    Identification of the Palmitoylation Site(s)  
From the analysis of a primary structure of the acylated GPCRs, it is known that the 
palmitoylation occurs exclusively on the cysteine residue(s) located in the cytoplasmic C-
terminus of the receptors. To identify the potential palmitoylation site(s) within the 5-
HT1A receptor, we constructed a series of the mutant receptors in which the C-terminal 
cysteine residues 417 and/or 420 were substituted by serine residues (Fig. 4.5 A). All 
mutants were expressed in the Sf.9 insect cells by the baculovirus system and labeled 
with either [35S]-methionine or [3H]-palmitic acid followed by immunoprecipitation, 
SDS-PAGE and fluorography. Labeling with [35S]-methionine revealed that the mutated 
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receptors were efficiently expressed along with the wild type (WT) receptor (Fig. 4.5 B, 
upper panel).  
 
Figure 4.5. The 5-HT1A Receptor is Palmitoylated on Two C-terminal Cysteine Residues, 
Cys417 and Cys420. (A) The amino acid sequence of the C-terminal domain of 5-HT1A receptor 
wild type is shown with a single-letter code. The serine residues substituting for the corresponding 
cysteine residues are shown in red. The extent of palmitoylation for the substitution mutants was 
determined by densitometry and calculated as the ratio of the [3H]-palmitate incorporation to the 
[35S]-methionine signal. The value obtained for the wild type 5-HT1A receptor was set to 100 %. The 
data are presented as means ± S. E. (n=4). (B) The 5-HT1A receptor wild type and substitution 
mutants were expressed in the Sf.9 cells, labeled either with [3H]-palmitate or [35S]-methionine and 
subjected to immunoprecipitation, SDS/PAGE and the fluorography. The exposure time was 3 days 
for [35S]-methionine and 42 days for [3H]-palmitate labeling. A representative fluorogram is shown. 
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The single substitution of either the C-417 or the C-420 resulted in a significantly 
decreased, although not completely blocked palmitoylation. The double mutant in which 
both of the cysteine residues were replaced by serines did not reveal any detectable 
incorporation of [3H]-palmitate even after the prolonged (6 weeks) exposure of the gel 
(Figure 4.5 B, lower panel). We quantified the level of palmitate incorporation for the 
individual mutants by densitometric analysis of the fluorograms after the [3H]-palmitate 
labeling in relation to the expression level defined by the [35S]-methionine incorporation. 
The analysis revealed that the incorporation of [3H]-palmitate into the C417-S and the 
C420-S mutants was reduced to 19.5 ± 6% (n = 4) and 19.1 ± 9% (n = 4), respectively, in 
comparison with the wild type. Thus, we concluded that both of the cysteine residues C-
417 and C-420 represent the palmitoylation sites on the 5-HT1A receptor.  
 
4.5.  Role of the Palmitoylation in the Coupling of the 
Receptor with G-proteins  
To test for the functional significance of the 5-HT1A receptor palmitoylation, we 
analysed the interaction of the 5-HT1A receptor with the Gα subunits of the heterotrimeric 
G-proteins by using the GTPγS coupling assay (Ponimaskin et al., 1998). First, the Gα-
subunits were co-expressed with the wild type receptor in Sf.9 cells (in all cases the 
appropriate Gα-subunit was co-expressed with the β1 and the γ2 subunits), and the 
agonist-promoted binding of [35S] GTPγS to the Gα-subunit was assessed by counting 
radioactivity directly after immunoprecipitation with the antibodies directed against the 
appropriate Gα subunit (Fig. 4.6 A). When the wild type 5-HT1A receptor was co-
expressed with Gαi1, Gαi2 or Gαi3, we measured a 1.7- to 2.5-fold increase in the [35S] 
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GTPγS binding upon stimulation with 1 µM 5-HT. The result confirmed that the 5-HT1A 
receptor effectively communicates with the G-proteins of the Gi family. In contrast, there 
was no coupling after co-expression of the receptor with the Gαs, the Gα12 or the Gα13 
subunits (Fig. 4.6 A).  
We then tested an ability of the palmitoylation-deficient receptor mutants to couple 
with the Gαi3 protein. In the case of the single mutants C417-S and C420-S, the agonist-
dependent GTPγS binding was significantly decreased, when compared to the WT 
receptor. However, some significant activation of the Gαi protein over the basal level was 
still detectable (Figure 4.6 B). In contrast, when the non-palmitoylated receptor mutant 
C417/420-S was expressed, the relative activation of the Gαi3 subunit after the agonist 
stimulation was completely abolished (Fig. 4.6 B). It is notable that the mutants as well 
as the WT 5-HT1A receptor were expressed in a similar level, as assessed by the Western 
blot analysis (Fig. 4.6 B, inset). To exclude the possibility that this effect was mediated 
by the change in the ligand binding properties, we performed the pharmacological 
analysis of the pharmacological of the wild type and the mutant 5-HT1A receptors 
expressed in the Sf.9 cells. We found that the pharmacological profile for the WT 
receptor was similar to that previously reported for the 5-HT1A receptor expressed in the 
Sf.9 cells (Clawges et al., 1997). More importantly, the analysis of the palmitoylation-
deficient mutants revealed that the replacement of the palmitoylated cysteines did not 
change their pharmacological properties (Fig. 4.7; Tab. 4.1). The binding affinity of [3H] 
5-HT for the wild type 5-HT1A receptor was similar to that obtained for the mutants. 
Taken together, these data indicate a functional importance of the 5-HT1A receptor 
palmitoylation for the coupling to the Gi3-protein. 
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Figure 4.6 Effect of Palmitoylation on the Coupling between the 5-HT1A Receptor and Gi-
Protein.  (A) Communication of the 5-HT1A receptor with different G-proteins. Membranes were 
prepared from the Sf.9 cells expressing the recombinant proteins as indicated and then incubated with 
[35S] GTPγS in the presence of either H2O (vehicle) or 5-HT (1 µM). The immunoprecipitations were 
performed with the appropriate antibodies directed against the indicated Gα-subunits. (B) The 
membranes were isolated from the Sf.9 cells co-expressing the recombinant Gαi3- and the Gβ1γ2-
subunits together with either the 5-HT1A receptor wild type or the acylation-deficient mutants. After 
the incubation with [35S] GTPγS in the presence of H2O (vehicle) or 1 µM 5-HT, the membranes 
were lysed and the Gαi3-subunit was immunoprecipitated with the specific antibodies. The values 
obtained for the 5-HT1A receptor wild type after the agonist stimulation were set to 100%. The data 
points represent the means ± S.E. (n=6). A statistically significant difference between values is noted 
(*, p < 0.01). (Inset) Expression analysis for the WT and the acylation-deficient mutants. Samples 
from the parallel infections were used for the Western blot analysis with the Gαi3- or the HA-specific 
antibodies. 
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Figure 4.7. Mutation of the Palmitoylation Sites Does Not Change the Ligand-Binding 
Properties of the 5-HT1A Receptor. Saturation binding of [3H] 5-HT with the WT and the 
palmitoylation-deficient 5-HT1A receptors was performed on the membranes prepared from infected 
Sf.9 cells. The non-specific binding did not exceed 5% of the specific binding and was subtracted 
from the total counts. Finally, the data were fitted to the one-site saturation model. Data points 
represent the means ± S.E. from at least three independent experiments performed in triplicate (n=9). 
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Table 4.1. Pharmacological Properties of the Palmitoylation-Deficient 5-HT1A Receptor Mutants 
Determined by the Saturation Binding of [3H] 5-HT to the Membranes of the Sf.9 Cells. The Kd and 
the Bmax values were calculated by the one-site saturation fit. Data are expressed in the means ± S. E. 
(n=9) 
 
WT C417-S C420-S C417/420-S 
Kd (nM) 140 ± 66 101 ± 44 110 ± 23 109 ± 23 
Bmax  0.590 ± 0.128 0.539 ± 0.044 0.473 ± 0.54 0.459 ± 0.082
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(pmol/mg protein) 
4.6.  Role of the Palmitoylation in the 5-HT1A Receptor 
Mediated Inhibition of the cAMP Formation  
These experiments were done in collaboration with A. Dumuis and M. Sebben, 
UPR CRNS, Montpellier, France.  
The functional role of the 5-HT1A receptor palmitoylation for the inhibition a cAMP 
formation was then tested in the mammalian cell system (Fig. 4.8). Here the ability of the 
wild type and the mutant receptors to inhibit the forskolin-stimulated cAMP 
accumulation was analysed upon application of the specific 5-HT1A receptor agonist 8-
OH-DPAT (Hamon et al., 1984). The NIH-3T3 cells that do not contain any detectable 
[3H]8-OH-DPAT binding sites (Varrault et al., 1992) were transfected with the 
pcDNA3.1(-) plasmid containing cDNA encoding for wild type and the acylation-
deficient mutants of the 5-HT1A receptor. The total expression level for the WT and the 
mutants was adjusted to 1500-1650 fmol/mg protein, which allowed for a quantitative 
analysis of the results.  
Expression of the WT 5-HT1A receptor resulted in the significant inhibition of the 
forskolin-promoted cAMP formation upon the receptor stimulation with the 8-OH-DPAT 
in a dose-dependent manner (Fig. 4.8 A). Replacement of any of the two palmitoylation 
sites was accompanied by a significant decrease in the capacity of the mutated receptors 
to inhibit the forskolin-stimulated cAMP formation. While the maximal inhibition of the 
cAMP formation obtained for the WT 5-HT1A receptor was 32 ± 3.6 %, for the 
palmitoylation-deficient mutants C417-S and C420-S this value was reduced to 17 ± 
2.4% and 22 ± 4%,  respectively  (Fig. 4.8 B).  In  the  case  of  the  non-acylated  5-HT1A  
  
Results 
 
80
 
Figure 4.8. Effect of the 5-HT1A Receptor Palmitoylation on the Inhibition of the Forskolin-
Stimulated Adenylate Cyclase Activity was evaluated in the NIH-3T3 cells transiently expressing 
the 5-HT1A receptor wild type, the C417-S, the C420-S and the C417/420-S mutants. (A). The 
intracellular cAMP level was measured after the treatment of the cells with forskolin at the increasing 
concentrations of 8-OH-DPAT. The data points represent means ± S.E. (n=12) (B). The effect of the 
saturating concentration (10-5 M) of 8-OH-DPAT. Levels of the cAMP accumulation were measured 
after 15-min incubation and expressed as a percentage of the cAMP accumulation in mock-transfected 
cells. The percentage conversion of [3H] ATP to [3H] cAMP in the mock transfected NIH-3T3 cells 
was 0.115 ± 0.013. Each value is the mean ± S.E. of at least four independent experiments, performed 
in triplicate. In all cases the level of the surface expression for the receptors was adjusted to 1500–
1650 fmol/mg protein.  M-mock  transfected  cells,  WT - wild type, 417 - C417-S, 420 - C420-S, 
417/420 - C417/420-S. 
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receptor mutant, the inhibitory potential of the receptor was completely abolished and 
exposure to agonists had no effect on the intracellular cAMP level (Fig. 4.8 B). Analysis 
of the dose-dependent inhibition of cAMP formation upon application of the 8-OH-
DPAT revealed that the EC50 value for the single mutants was approximately 2.5 times 
higher than that obtained for the WT 5-HT1A receptor. We calculated an EC50 of 127 ± 4 
nM for the Cys417-Ser, 140 ± 7 nM for the Cys420-Ser mutants and 52 ± 6 nM for the 
WT. These data confirmed the results obtained for Gαi3 coupling in the Sf.9 insect cells 
and point to a functional significance of the 5-HT1A receptor palmitoylation in the Gαi-
mediated signaling. 
 
4.7.  Activation of the Erk 1/2 by the 5-HT1A Wild type 
Receptor and the Acylation Deficient Mutants  
In addition to the Gαi-mediated inhibition of the adenylate cyclase, the 5-HT1A receptor 
modulates the activity of the extracellular signal-regulated kinase (Erk) via a Gβγ-
mediated pathway (Garnovskaya et al., 1996). The Erk is switched to the activated form 
by its phosphorylation on the threonine 202 and the tyrosine 204 residues. Therefore, we 
analysed the ability of the 5-HT1A receptor WT and the palmitoylation-deficient mutants 
to activate the Erk by the Western blot analysis with the antibodies directed against the 
phosphorylated form of the Erk 1/2. In parallel, the expression level of the Erk 1/2 as 
well as of the 5-HT1A receptor was verified by a Western blot with antibodies against the 
total Erk or against the HA-epitope, respectively. The surface expression level for the 
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WT and the mutant receptors was adjusted to 450-500 fmol/mg protein, which allowed 
for the quantitative analysis of the results.  
Figure 4.9. Activation of the Erk 1/2 kinase by the 5-HT1A Receptor Wild Type and Acylation-
Deficient Mutants. (A) The CHO cells were transiently transfected with the 5-HT1A receptor WT or 
mutants. In all cases the receptor surface expression was adjusted to 450-500 fmol/mg protein as 
assessed by the ligand binding. The transfected cells were treated with 10 µM 8-OH-DPAT or H2O 
(vehicle) for 5 min. The proteins were analysed by SDS/PAGE and Western blot. The membranes 
were probed either with the antibodies raised against the total (phosphorylated and non-
phosphorylated) Erk (upper panel) or against the phosphorylated Erk (lower panel). To analyse the 
5-HT1A receptor expression, the membranes were probed with the antibodies raised against the HA-
epitope (right panel). Fluorograms are representative of four independent experiments. (B) 
Quantification of the Erk phosphorylation for the receptor WT and the substitution mutants was 
performed by densitometry and calculated as the ratio of the Erk phosphorylation signal normalized 
to the total Erk expression. Each value represents the mean ± S.E. (n = 4). The statistically 
significant differences between the values are noted (*, p<0.05; **, p<0.01) 
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Figure 4.9 demonstrates that the agonist treatment of the CHO cells transiently 
transfected with the WT 5-HT1A receptor resulted in the approximately 8-fold increase of 
the phosphorylation and thus of the activation of the Erk 1/2. For the single acylation 
mutants C417-S and C420-S we obtained a significantly reduced increase (approximately 
4-fold) of the agonist-induced Erk 1/2 phosphorylation. In the case of the non-acylated 
mutant C417/420-S, treatment with the agonist induced only a very weak increase 
(approximately 1.8-fold) in the phosphorylation of the Erk. These data suggest the 
importance of the 5-HT1A receptor palmitoylation for the signaling through the Gβγ-
mediated pathway, in addition to the Gαi-mediated signaling. 
 
4.8. Possible Role of the Palmitoylation for the Targeting of 
the 5-HT1A Receptor to the Detergent-Resistant Membrane 
Subdomains 
Palmitoylation has been shown to be involved in the recruitment of several proteins 
to the membrane subdomains, like lipid rafts or caveolae. Therefore, we compared the 
distribution of the wild type and the palmitoylation–deficient mutant (C417/420-S) of the 
5-HT1A receptor in the detergent-resistant membrane subdomains (DRMs). For that, NIH-
3T3 cells stably expressing for either the wild type or the mutant receptor were 
solubilised in the cold Triton-X100 and the lysates were subjected to the 
ultracentrifugation in the OptiprepTM density gradient, as described in “Experimental 
procedures”. The immunoblot analyses of the gradient fractions prepared from the cells 
stably expressing the wild type 5-HT1A-YFP (surface expression of 304±62 fmol/mg 
protein) (Fig. 4.10 A) demonstrated that the portion of the 5-HT1A receptor was located in 
  
Results 
 
84
the low density membrane fractions 3 and 4 (30 % and 25 % OptiprepTM, respectively). 
The DRM-located buoyant part of the Gαi3 protein and the caveolae marker Caveolin 1 
were also located in these fractions. The major fraction of the wild type receptor was, 
however, localized in the high density fractions 1 and 2 (40 % and 35 % OptiprepTM) 
(Fig. 4.10 A). The distribution of a non-DRM marker transferrin receptor was limited to 
the high density fractions 1 and 2. Interestingly, the palmitoylation-deficient mutant 
C417/420-S stably expressed in the NIH-3T3 cells (surface expression of 635±64 
fmol/mg protein) was apparently depleted from the low density fractions 3-4, while 
distribution of the Gαi3 protein, the caveolin 1 and the transferrin receptor was not 
affected (Fig. 4.10 A). Quantitative analysis of the fluorograms revealed that 
approximately 30 % of the wild type receptor are localized in the low density fractions 3 
and 4, while in the case of C417/420-S mutant only the fraction of approximately 4% was 
found in the low density fractions (Fig. 4.10 B). Similar distribution was found when the 
HA-tagged wild type and the acylation-deficient C417/420-S mutant 5-HT1A receptors 
were transiently expressed in the CHO cells (data not shown). 
It has been shown that an integrity of the DRMs can be disturbed by the specific 
cholesterol depletion (Harder et. al. 1998). Thus, amount of the DRM-associated proteins 
in the low density fractions can be reduced by the treatment of the cells with the 
cholesterol-depleting agent methyl-β-cyclodextrin prior to the lysis. This can serve as an 
additional specific test for the localization of the proteins in the buoyant cholesterol-
enriched membrane subdomains. Localization of the wild type 5-HT1A receptor and the 
Gαi protein in the low density gradient fraction was sensitive to the cholesterol depletion. 
As shown in the Fig. 4.11, when the NIH-3T3 cells stably expressing the wild type 5-
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HT1A receptor were treated with the methyl-β-cyclodextrin prior to the Triton-X100 lysis, 
the amount of both the receptor and the Gαi protein in the low density fractions 3 and 4 
was decreased, while the distribution of the non-DRM marker transferrin receptor did not 
change (Fig. 4.11). Altogether, these data suggest that the palmitoylation of the 5-HT1A 
receptor may represent the signal for the receptor targeting to the cholesterol enriched 
DRMs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Results 
 
86
Figure 4.10. Mutation of the Palmitoylation Sites Affects Location of the 5-HT1A Receptor in 
the Detergent-Resistant Membranes. The NIH-3T3 cells stably expressing either the YFP-tagged 
wild type 5-HT1A receptor or the Cys417/420-Ser mutant, were lysed with the cold 1% Tryton-X100 
and the lysates were ultracentrifugated in the OptiprepTM density gradient. The gradient fractions 
were analysed by SDS-PAGE and Western Blot. (A) The wild type 5-HT1A-YFP (about 80 kDa) is 
enriched in the low density fractions 3 and 4 together with the Gαi protein and the Caveolin 1, while 
the mutant C417/420-S receptor is almost excluded from these fractions. The transferrin receptor was 
used as the non-DRM marker. Numbers of the gradient fractions (see Tab. 3.11 in „Experimental 
procedures“) are shown on the top of the fluorograms. The bottom and the top of the gradients are 
indicated below. The low density DRM fractions are highlighted by the red bar. (B). Relative amount 
of the receptor in the high density fractions 1+2 and the buoyant low density fractions 3+4. The 
quantitative analysis of the receptor distribution was performed by densitometry and calculated in 
percentage of the total of the all fractions. Data shown in means (n=3). The data range is shown by 
bars.   
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Figure 4.11. Cholesterol Depletion Reduces Localization of the Wild Type 5-HT1A Receptor and 
the Gαi Protein in the Detergent-Resistant Membranes. The NIH-3T3 cells stably expressing the 
YFP-tagged wild type 5-HT1A receptor were treated with 15 mM MβCD for 45 minutes (+CD) or left 
untreated (-CD), lysed with cold  1% Tryton-X100 and the lysates were subjected to the 
ultracentrifugation in the OptiprepTM density gradient. The gradient fractions were analysed by SDS-
PAGE and Western Blot. Representative fluorogram is shown (n=3). Numbers of the gradient 
fractions (see Tab. 3.11 in „Experimental procedures“) are shown on top of the fluorograms. The 
bottom and the top of the gradients are indicated below. The low density fractions, containing the 
DRM, are highlighted by the red bar. 
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5. DISCUSSION 
5.1 Expression and Palmitoylation of the 5-HT1A 
Receptor 
The covalent attachment of the palmitic acid to proteins (acylation) is often a 
reversible modification, and the dynamic acylation has been demonstrated for a number of 
signaling proteins, including the G-protein coupled receptors (GPCR). In the present 
work, we demonstrate the palmitoylation of the 5-HT1A serotonin receptor using the 
recombinant baculovirus expression in insect cells (Fig. 4.1 and 4.2A). The sensitivity of 
this modification to the nucleofilic and to the reducing agents (Fig. 4.2 B and C) indicated 
that the palmitic acid is attached to the receptor via a thioester linkage, presumably to the 
free sulfhydril group on cystein residue(s). 
Treatment of the cells with the inhibitor of protein synthesis cycloheximide led to 
the diminished incorporation of [3H]-palmitate into the receptor, indicating that there is no 
significant turn-over of the receptor-bound palmitate (Fig. 4.3 A). Furthermore, the results 
of the long-time pulse-chase experiments indicated that the fatty acid was stably attached 
to the receptor (Fig. 4.3 B), suggesting that the palmitoylation of the 5-HT1A receptor is 
irreversible. Such stable palmitoylation is still unusual for the signaling proteins, in 
particular for the GPCRs that generally undergo repeated cycles of palmitoylation and 
depalmitoylation. The observed low rate of the palmitate exchange suggests that the 
depalmitoylation reaction is blocked or extremely slow. The resistance of the receptor-
bound palmitate to the cleavage by thioesterases may be explained by the inaccessibility 
of the 5-HT1A receptor palmitoylation site(s) to the depalmitoylating enzyme(s). This may 
be mediated by the orientation of the palmitate group within the membrane as well as by 
  
Discussion 
 
89
the composition of neighbouring amino acids (see below). Alternatively, the very short 
(18 aa) C-terminus of the 5-HT1A receptor could lack the specific motif(s) required for the 
recognition by the thioesterase.  
Palmitoylation of several GPCRs, including β2- and α2A-adrenergic, dopamine D1, 
muscarinic acetylcholine m2 and 5-HT4(a) receptors, have been shown to be regulated by 
the agonist (Bouvier et al., 1995b; Hayashi and Haga, 1997; Kennedy and Limbird, 1994; 
Loisel et al., 1996; Ng et al., 1994; Ponimaskin et al., 2001). On the contrary to these data, 
the agonist stimulation of the recombinant 5-HT1A receptor did not cause any changes in 
its palmitoylation efficiency (Fig. 4.4). Since it has been reported that the recombinant 5-
HT1A receptor couples effectively to the endogenous Go-like proteins in the insect cells 
(Mulheron et al., 1994), we suggest that the agonist-independent palmitoylation obtained 
here reflects the real physiological situation. Moreover, the results obtained after the co-
infection of the Sf.9 cells with the recombinant Gi-protein are further confirming the 
agonist-independence of the 5-HT1A receptor palmitoylation also in the coupled system.  
 
5.2. Sites of the 5-HT1A Receptor Palmitoylation 
From the analysis of the palmitoylated GPCRs, it is known that palmitoylation 
occurs on the cystein residues located in the C–terminal juxta-membrane region of the 
receptors (Qanbar and Bouvier, 2003). The 5-HT1A receptor possesses two cystein 
residues within its C-terminal cytoplasmic domain, Cys417 and Cys420. These residues 
are conserved among the human, the rat and the murine 5-HT1A receptors (Charest et al., 
1993). The replacement of the both Cys417 and Cys420 by serines resulted in the non-
palmitoylated 5-HT1A receptor (Fig. 4.5). The replacement of the single cystein residues 
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Cys417 or Cys420 led to an approximately 80% reduction of the palmitoylation, when 
compared with the wild type 5-HT1A receptor, suggesting the positive cooperativity 
between the palmitoylation of the Cys417 and the Cys420 residues.  
In order to gain better insights into the molecular mechanisms of the 5-HT1A 
receptor signaling and to search for the specific biological functions, we further analysed 
the palmitoylation-deficient mutants for their ability to activate the 5-HT1A receptor 
specific signaling pathways. 
 
5.3. Functional Role of the 5-HT1A Receptor 
Palmitoylation 
Multiple studies of the palmitoylated GPCRs did not reveal a common function for 
the receptor palmitoylation. It has been shown that palmitoylation may be involved in 
several aspects of the GPCR function, from ensuring the expression of functional 
receptors on the cell surface (Blanpain et al., 2001; Fukushima et al., 2001) to various 
aspects of the signal transduction (Hayashi and Haga, 1997; O'Dowd et al., 1989; 
Okamoto et al., 1998b) and the receptor desensitization and downregulation (Bradbury et 
al., 1997; Eason et al., 1994; Hukovic et al., 1998; Kraft et al., 2001). Therefore we 
analysed the possible functional role of the 5-HT1A receptor palmitoylation for the 
coupling with the heterotrimeric G-proteins and for the modulation of the downstream 
signaling cascades, including the stimulation of the mitogen-activated protein kinase 
(Erk2) mediated by Gβγ subunit and the inhibition of the forskolin-stimulated cAMP 
formation mediated by the Gαi subunit. 
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Characterization of the acylation-deficient 5-HT1A mutants revealed that the 
palmitoylation at either the Cys417 or the Cys420 residue was still sufficient to maintain 
the interaction of the mutant receptors with the Gi-protein in the membranes of the Sf.9 
cells coexpressing the receptor and the Gi protein, although to a significantly lower extent 
than the WT receptor (Fig. 4.6, 4.8 and 4.9). Mutation of the both palmitoylation sites 
completely abolished coupling of the receptor with the Gi protein, indicating that the 
palmitoylation of the 5-HT1A receptor is critically involved in the signal transduction. The 
importance of the palmitoylation for the signal transduction by the 5-HT1A receptor was 
further confirmed by the analysis of the receptor-mediated inhibition of the forskolin-
stimulated cAMP formation (Fig. 4.8) and the Erk 1/2 phosphorylation (Fig. 4.9) 
The data on the important functional role played by the 5-HT1A receptor 
palmitoylation for the signal transduction are consistent with the recent reports 
demonstrating the importance of the palmitoylation of the β2-adrenergic and the 
endothelin-B receptors for the agonist-stimulated coupling to Gαs and to both Gαq and 
GαI proteins, respectively (Moffett et al., 1993; O'Dowd et al., 1989; Okamoto et al., 
1998b). The recent data on the CCR5 and the prostacyclin receptors also demonstrated 
that the receptor palmitoylation is significantly involved in the G protein coupling and the 
effector signaling (Blanpain et al., 2001; Miggin et al., 2003). On the other hand, this is in 
contrast with the recent results obtained for the 5-HT4(a) receptor. The palmitoylation of 
this receptor was shown to regulate the constitutive receptor activity and was not critically 
involved in the coupling between the receptor and the Gs-protein after the agonist-
stimulation (Ponimaskin et al., 2002a). Similar results have been also reported for the α2-
adrenergic receptor which remained functionally coupled to the Gi protein after the 
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elimination of the palmitoylation site (Kennedy and Limbird, 1993). In the case of the µ2-
muscarinic receptor, it has been shown that the C-terminal Cys457 is not required for the 
receptor-mediated inhibition of the AC activity (van Koppen and Nathanson, 1991), 
although its mutation decreases the ability of the receptor to activate the Gi protein 
(Hayashi and Haga, 1997). These opposing findings demonstrate that there is no common 
function for the acylation applicable to all GPCRs, and a thorough analysis of each 
individual receptor is therefore necessary. 
How can the palmitoylation of the 5-HT1A receptor mediate the communication 
between the receptor and the Gi protein? Since the subcellular distribution (data not 
shown), the surface expression level and the pharmacological properties of 
palmitoylation-deficient mutants (Fig. 4.7 and table 4.1) are quite similar to those 
obtained for the receptor wild type, we exclude the differences in the intracellular receptor 
trafficking and the agonist binding as possible reasons for the impaired Gi protein 
activation. Alternatively, there are two ways in which palmitoylation could affect the 
receptor functions: (i) the palmitoylation may be required to assume the proper 
conformation of the 5-HT1A receptor needed either for the receptor/G protein recognition 
and the binding process and/or for the receptor-mediated G protein activation or (ii) the 
palmitoylation may be essential for the receptor localization in the specific membrane 
subdomains, like the lipid rafts.  
It has been proposed that the palmitoylation of the GPCRs may provide a lipophylic 
membrane anchor to create an additional fourth intracellular loop in the carboxyl-terminal 
region of the receptor (Bouvier et al., 1995a; Ross, 1995). More recently, direct evidence 
for this idea has been obtained for the rhodopsin (Moench et al., 1994; Palczewski et al., 
2000). Since the 5-HT1A receptor possesses the double acylation site within the C-
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terminal domain (Fig. 4.5), the complete receptor palmitoylation may result in the 
formation of the additional small intracellular loop as proposed in Fig.5.1. The fact that 
the 5-HT1A receptor remains in the continuous palmitoylation state suggests the tight and 
irreversible association with the plasma membrane. Such membrane association may be 
further stabilized by basic amino acids surrounding the palmitoylated cystein residues 
(Fig. 5.1). According to the two-signal model for membrane binding (Resh, 1999; 
Wedegaertner, 1998), the combination of the palmitate and basic motif may provide stable 
and essentially irreversible binding of the intracellular C-terminal domain with the plasma 
membrane. Functionally, the resulting conformation of the C-terminal domain may 
represent the structural determinant important for the communication with Gi proteins. 
Mutation of the single acylation site will result in the more transient interaction of the 
receptor C-terminus with the membrane. Although such conformation will be still 
sufficient for the interaction with the Gi protein in some extent, the general coupling 
efficiency will be reduced. Replacement of both palmitoylated cysteines may destroy the 
fourth loop and therefore abolish the Gi-mediated receptor activity.  
An intriguing alternative mechanism could be the involvement of the palmitoylation 
in trafficking of the 5-HT1A receptor to specific membrane subdomains. Palmitoylation 
has been reported to be important for the enrichment of several acylated proteins in the 
detergent-resistant membranes (DRM), like the caveolae and the lipid rafts (Fragoso et al., 
2003; Hiol et al., 2003; Kalinina and Fricker, 2003; Li et al., 2002; Melkonian et al., 
1999; Moffett et al., 2000; Niethammer et al., 2002; Patterson, 2002). Assuming that the 
palmitoylation of the 5-HT1A receptor may represent a signal for the DRM trafficking, it 
could be suggested that the removal of one or both palmitate chains from the 5-HT1A 
receptor will reduce its association with the DRMs. Indeed, our preliminary data on the 
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cell fractionation suggest that approximately a 30 % of the wild type 5-HT1A receptor is 
localized in the TritonX-100 insoluble, low density membrane fractions together with the 
Gi protein (Fig. 4.10). Moreover, the presence of the 5-HT1A receptor in the DRM 
fractions was reduced upon the cholesterol depletion (Fig. 4.11), confirming that the 
partial buoyancy of the 5-HT1A receptor could be due to its localization in the cholesterol-
enriched plasma membrane fractions, like the lipid rafts or the caveolae.  
 
Figure 5.1. Proposed Structure for the C-terminal Domain of the 5-HT1A Receptor. The seventh 
transmembrane domain as well as the amino acid sequence of C-terminal cytoplasmic tail of the 5-
HT1A receptor are shown schematically. The basic residues are marked by “+”. A cluster of basic 
residues can provide electrostatic interaction with the inner leaflet of the membrane bilayer. Two 
palmitate moieties provide additional hydrophobic interaction with membrane, therefore resulting in 
more persistent association. In combination, these two signals can contribute to the formation of a 
stable intracellular loop. 
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In contrary, the nonpalmitoylated C417/420-S mutant was significantly depleted 
from the low density fractions, being represented there only by approximately 4% of the 
total receptor amount (Fig. 4.10). Since the detergent-resistant membrane subdomains 
have been proposed to maintain the different components of a particular signaling system 
OOH
  
Discussion 
 
95
together, therefore representing the “hot spots” for signaling (Huang et al., 1997), the non-
DRM localization of the 5-HT1A receptor may result in the uncoupling from the 
Gi/adenylate cyclase signaling pathway. Indeed, partial localization in the DRM was 
shown to be critical for the signal transduction by several G protein coupled receptors. For 
example, it has been shown that the small fraction (10%) of the endothelin B (ETB) 
receptor is more resistant to the ligand-promoted internalization the non-DRM localized 
ETB receptors, thus allowing it to couple to specific signaling pathways (Chini and Parenti 
2004). Additional studies, involving novel state-of-art methods for the investigation of the 
plasma membrane subdomains like the co-patching of the membrane components by 
external crosslinking agents (Harder et al., 1998) and electron microscopy are necessary 
to establish whether the stable palmitoylation of the 5-HT1A receptor is involved in the 
partial DRM trafficking and confers the colocalization of the receptor with its signaling 
partners. 
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6. SUMMARY 
In the present study, we demonstrated that the mouse 5-hydroxytryptamine (1A) (5-
HT1A) receptor is modified by the palmitic acid, that is covalently attached to the protein 
through the thioester-type bond. The palmitoylation efficiency was not modulated by the 
receptor stimulation with the agonist. Block of the protein synthesis by cycloheximide 
resulted in the drastic decrease of the receptor acylation, suggesting that the 
palmitoylation occurs early after the synthesis of the 5-HT1A receptor. Furthermore, the 
pulse-chase experiments demonstrate that the fatty acids are stably attached to the 
receptor.  
Two conserved cystein residues C417 and C420 located in the cytoplasmic C-
terminal domain were identified as the palmitoylation sites by the site-directed 
mutagenesis. To address the functional role of the 5-HT1A receptor palmitoylation, we 
analysed the ability of the palmitoylation-deficient mutants to interact with the 
heterotrimeric Gi protein and to modulate the downstream effectors. Replacement of the 
individual cystein residues (C417 or C420) resulted in the significantly reduced coupling 
of the receptor with the Gi protein and in the impaired inhibition of the adenylate cyclase 
activity. When both palmitoylated cysteines were replaced, the communication of the 
receptors with the Gi proteins was completely abolished. Moreover, the non-palmitoylated 
mutants were no longer able to inhibit the forskolin-stimulated cAMP formation, 
indicating that the palmitoylation of the 5-HT1A receptor is critical for the interaction with 
the heterotrimeric Gi proteins. The receptor-dependent activation of the extracellular 
signal-regulated kinase was also affected by the acylation-deficient mutants, suggesting 
the importance of the receptor palmitoylation for the signaling through the Gβγ-mediated 
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pathway, in addition to the Gαi-mediated signaling. In addition, we demonstrated that the 
palmitoylation may be involved in the partial targeting of the 5-HT1A receptor to the 
detergent-resistant membrane subdomains.  
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